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ABSTRACT 
Coronaviruses comprise a large family of viruses within the order Nidovirales 
containing single-stranded positive-sense RNA genomes of 27-32 kilobases. 
Divided into four genera (alpha, beta, gamma, delta) and multiple newly defined 
subgenera, coronaviruses include a number of important human and livestock 
pathogens responsible for a range of diseases. Historically, human 
coronaviruses OC43 and 229E have been associated with up to 30% of common 
colds, while the 2002 emergence of severe acute respiratory syndrome-
associated coronavirus (SARS-CoV) first raised the specter of these viruses as 
possible pandemic agents. Although the SARS-CoV pandemic was quickly 
contained and the virus has not returned, the 2012 discovery of Middle East 
respiratory syndrome-associated coronavirus (MERS-CoV) once again elevated 
coronaviruses to a list of global public health threats. The genetic diversity of 
these viruses has resulted in their utilization of both conserved and unique 
mechanisms of interaction with infected host cells. Like all viruses, coronaviruses 
encode multiple mechanisms for evading, suppressing, or otherwise 
circumventing host antiviral responses. Specifically, our lab has studied 
coronavirus interactions with antiviral pathways activated by the presence of 
cytoplasmic viral double-stranded RNA (dsRNA) such as OAS-RNase L and 
interferons (IFN). Previous work from our lab demonstrated that the murine 
coronavirus mouse hepatitis virus (MHV) uses a phosphodiesterase (PDE) to 
suppress RNase L activation. We have also now shown that additional viruses 
within Nidovirales encode similar PDEs that suppress RNase L activation in the 
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context of chimeric MHV, and that a PDE encoded by MERS-CoV, the NS4b 
accessory protein, inhibits RNase L in its native context. I have further shown 
that MERS-CoV NS4b is a unique PDE with additional functions inhibiting the 
IFN response, a role dependent on both nuclear localization and its catalytic 
activity. 
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Chapter 1 
INTRODUCTION:  
HUMAN CORONAVIRUSES AND INTERACTIONS WITH 
INNATE IMMUNITY 
  
 2 
General Introduction to Coronavirus Biology  
 
Coronavirus genome structure, replication, and transcription 
Coronaviruses fall within the Cornidovirineae suborder, family 
Coronaviridae, and subfamily Orthocoronavirinae of the order Nidovirales. These 
viruses are grouped together for their unique genome organization, ribosomal 
frameshift in the first open reading frame, and expression of 3’ structural and 
accessory genes via transcription of nested, subgenomic mRNAs (1). Also within 
the order Nidovirales is the suborder Tornidovirineae which includes the genus 
Torovirus, that includes the toroviruses, which are distinguished from 
coronaviruses primarily by differences in their accessory genes. The most 
notable feature of coronaviruses is their extraordinary genome size of up to 32 
kilobases, among the largest RNA genomes, which is capped at the 5’ end and 3’ 
polyadenylated. Recently, two nidoviruses have been discovered with genomes 
of 36 and 41 kilobases in length, highlighting the increase in coding capacity 
afforded by the expression of a viral proofreading exonuclease and a non-
icosahedral nucleocapsid (1-4). 
 
The 5’ ~20 kb of the coronavirus genome comprises the replicase gene 
(ORF1ab), which is translated from the genome as a single polyprotein and 
proteolytically processed into up to 16 constituent non-structural proteins (nsp). 
In the majority of translation events, protein synthesis terminates at the end of 
ORF1a while a low-frequency ribosomal frameshift allows translation of the full 
length ORF1ab. Downstream of the conserved replicase gene, in the 3’ 10 kb of 
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the genome, are the coronavirus structural genes. The four major structural 
genes, in their 5’à3’ order are spike (S), memberane (M), envelope (E), and 
nucleocapsid (N). Some viruses within the Betacoronavirus genus contain a fifth 
structural gene, hemagglutinin-esterase (HE) (1). Interspersed in the 3’ region 
are genes encoding non-structural (NS) accessory proteins, which are unique to 
distinct genera and subgenera of coronaviruses and often mediate critical 
interactions between the virus and host innate immune pathways. As such, these 
genes and the proteins they encode have been of particular interest to the Weiss 
laboratory. 
 
As with other positive sense ssRNA viruses, coronavirus replication and 
transcription occurs at ER-derived and localized replication-transcription 
complexes (RTCs) that are formed by several of the non-structural proteins and 
contain the RNA-dependent RNA polymerase (nsp12), RNA primase (nsp8), 
RNA helicase (nsp13), and RNA proofreading exonuclease (nsp15) among other 
viral and host proteins (1). While ORF1ab translation occurs directly from the 
genome, synthesis of all other proteins requires transcription of nested 
subgenomic mRNAs which is regulated by a transcription regulatory sequence 
(TRS) upstream of each structural and accessory gene (5). The first step in this 
unusual process is transcription of a negative-sense subgenomic (sg) RNA 
corresponding to each gene. The negative-sense sgRNA is joined to a leader 
sequence from the 5’ end of the genome and used as a template for viral mRNA 
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synthesis, with in most cases only the 5’ gene of each subgenomic mRNA being 
translated. 
 
Coronaviridae phylogeny 
The taxonomic organization of the order Nidovirales was substantially 
revised in July 2018 by the International Committee on the Taxonomy of Viruses. 
Previously, the family Coronaviridae comprised two sub-families, Coronavirinae 
and Torovirinae which contained the coronaviruses and toroviruses, respectively. 
Under the 2018 revision, Nidovirales is now divided into seven sub-orders with 
the coronaviruses reclassified into the sub-order Cornidovirineae, family 
Coronaviridae, sub-family Orthocoronavirinae (Fig 1.1). Subordinate to this sub-
family, they are further divided into four genera: Alphacoronavirus, 
Betacoronavirus, Gammacoronavirus, and Deltacoronavirus that are further 
separated into numerous subgenera (Fig 1.1). The majority of human and 
agricultural pathogens among the coronaviruses fall within Alphacoronavirus and 
Betacoronavirus, divided into twelve and five subgenera, respectively. 
  
The human upper 
respiratory tract pathogen 
human coronavirus 229E 
(HCoV-229E) and HCoV-
NL63 are among the 
alphacoronaviruses, 
Figure 1.1 Simplified view of coronavirus taxonomy.  
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along with the highly virulent agricultural pathogen porcine epidemic diarrhea 
virus (PEDV) (6, 7).  Betacoronavirus had previously been divided into four 
lineages (A-D), but now consists of the subgenera Embecovirus (HCoV-OC43, 
HCoV-HKU1, mouse hepatitis virus/MHV), Hibecovirus (bat Hp-betacoronavirus 
Zhejiang 2013), Merbecovirus (MERS-CoV, MERS-like bat coronaviruses), 
Nobecovirus (Rousettus bat coronavirus HKU9), and Sarbecovirus (SARS-CoV, 
SARS-like bat coronaviruses). The distinction between the Betacoronavirus 
subgenera lies in the degree of sequence similarity between their replicase 
genes and the suite of accessory genes they contain, while the basic genomic 
organization is highly conserved. Aside from providing taxonomic classification, 
the accessory genes likely underlie virus-host interactions that are unique 
between subgenera. Further, they are likely acquired from host organisms or via 
horizontal gene transfer with other coronaviruses or unrelated viruses, as 
appears to have occurred with a recently discovered deltacoronavirus that 
contains a small reovirus-derived open reading frame (8). 
 
The toroviruses, previously grouped into Coronaviridae with the 
coronaviruses, are now in their own suborder Tornidovirineae, family 
Tobaniviridae, and subfamily Torovirinae, which contains the genus Torovirus. 
These viruses are primarily characterized as agricultural pathogens, the best 
studied of which is equine torovirus, with the most intensively studied variant 
known as Berne virus (BEV) (9). 
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History and Origin of Human Coronaviruses 
 
Common cold-causing coronaviruses 
For several decades preceding the 2002 emergence of SARS-CoV human 
coronaviruses were understood as etiological agents of the common cold. HCoV-
229E, an Alphacoronavirus, was first isolated from the respiratory tract of 
common cold patients in 1966 (10) while HCoV-OC43 was isolated the following 
year from patients with similarly mild respiratory disease (11). Though viral 
taxonomy was in its infancy at this time, both viruses were quickly recognized as 
morphologically highly similar to avian infectious bronchitis virus (IBV) (11, 12), 
now classified as a gammacoronavirus. HCoV-OC43 was identified as 
serologically related to MHV while HCoV-229E was found to be serologically 
distinct, a classification that is borne out by the genetic similarity between MHV 
and HCoV-OC43 as betacoronaviruses of the same subgenus (Embecovirus) 
(11). While the isolation conditions of both HCoV-OC43 and HCoV-229E 
suggested they cause a cold-like disease, experimental infection of healthy 
volunteers confirmed these original observations (13). 
 
Although these viruses have been known and studied for several decades, 
recent work has begun to shed light on their origins, which appear to have 
similarities with the more recent zoonotic emergence of SARS-CoV and MERS-
CoV. While HCoV-OC43 was initially classified serologically as closely related to 
MHV, later studies identified an even greater degree of antigenic similarity with 
bovine coronavirus (BCoV) (14). Subsequent studies of HCoV-OC43, MHV, and 
 7 
BCoV partial genome sequences revealed that HCoV-OC43 is most closely 
related to BCoV and that the two viruses likely diverged relatively recently (15, 
16). The HCoV-OC43 complete genomic sequence was reported in 2005 and 
firmly established its close genetic relationship with BCoV (17). In all ORFs, 
BCoV is the closest relative to HCoV-OC43 with the exception of the E gene, 
which is more closely related to its ortholog from porcine hemagglutinating 
encephalomyelitis virus (PHEV), suggesting a recombination event between 
BCoV and PHEV may have preceded the emergence of HCoV-OC43 (17). This 
study further suggested that although HCoV-OC43 has circulated throughout the 
human population for several decades, its origin bears more in common with 
SARS-CoV and MERS-CoV than previously understood. A molecular clock 
analysis suggested that BCoV and HCoV-OC43 may have had a common 
ancestor as recently as the year 1890, and that HCoV-OC43 originated through 
zoonotic transmission from a livestock source, similar to the spillover of MERS-
CoV from dromedary camels to humans (17). Since its zoonotic transmission, 
HCoV-OC43 has become a globally ubiquitous cause of common colds and 
exhibits considerable genetic diversity indicative of its continuous transmission 
among humans (18, 19). 
 
As with HCoV-OC43, recent work has illuminated a relatively recent 
zoonotic origin for HCoV-229E, which with HCoV-OC43 and the 
Alphacoronavirus HCoV-NL63 is responsible for 10-30% of common colds (20). 
The ecological origins of HCoV-229E now appear to have much in common with 
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those of SARS-CoV and particularly MERS-CoV. The clarification of these origins 
began with the 2005 report of partial genome sequences of a novel 
alphacoronavirus recovered from bats of the species Miniopterus pusillus in 
Hong Kong (21). Subsequently, RNA was detected from bats in Ghana 
representing a different novel alphacoronavirus closely related to HCoV-229E, 
suggesting that like numerous other emerging zoonotic viruses, HCoV-229E may 
have originated in bats (22). Most recently, several HCoV-229E-like viruses were 
successfully isolated from dromedary camels (23). The best available evidence 
suggests that the HCoV-229E lineage originated among African bats and entered 
the human population via an intermediate reservoir in dromedaries, where an 
ORF8 deletion that distinguishes bat from human variants appears to have 
emerged (24, 25). 
 
In the 21st century, between the SARS-CoV pandemic and discovery of 
MERS-CoV, two additional human coronaviruses were discovered. The first of 
these, HCoV-NL63, was isolated in 2003 in the Netherlands from a hospitalized 
child (26) and characterized as a novel alphacoronavirus. That study and others 
(20, 26) have identified HCoV-NL63 as a continuously circulating cause of 
frequently mild respiratory infection, though like HCoV-OC43 and HCoV-229E it 
is capable of causing moderate to severe disease in particularly susceptible 
hosts (20). As with HCoV-229E, recent work has uncovered a close evolutionary 
relationship with currently circulating alphacoronaviruses of bats (27), bolstering 
the emerging consensus that the Alphacoronavirus and Betacoronavirus genera 
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have their origins in bats (28, 29). Interestingly, given the dramatic differences in 
virulence between HCoV-NL63 and SARS-CoV, they both utilize the cell-surface 
protease ACE-2 as an entry receptor (30, 31). 
 
A fourth human coronavirus, the novel betacoronavirus HCoV-HKU1, was 
isolated from a hospital patient in Hong Kong in 2004 (32). A rapid follow-up 
study in Hong Kong determined that HCoV-HKU1 circulates throughout the year, 
causing primarily mild respiratory disease (33). Continued molecular 
epidemiology and surveillance studies have revealed similar patterns of HCoV-
HKU1 infection in Europe (34) and the United States (35, 36). Overall, it appears 
to cause a similar percentage of respiratory infections as HCoV-229E, and both 
are somewhat less prevalent than HCoV-OC43 (36). Like HCoV-NL63, HCoV-
HKU1 clinical isolates replicate in primary human airway epithelial (HAE) cell 
cultures (37, 38) but the inability to propagate these viruses on established cell 
lines has limited efforts to understand their basic biology. 
 
Collectively, in addition to being responsible for 10-30% of common colds, 
these four viruses cause or contribute to an unknown burden of severe disease 
among the very young, very old, or immunocompromised. Thus, even before 
consideration of the potential threat posed by more virulent zoonotic 
coronaviruses, the endemic human coronaviruses are responsible for a 
significant disease burden. Despite this, surprisingly little is known about their 
basic biology beyond that which is likely conserved with more extensively studied 
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coronaviruses. Partly this is a result of difficulties in culturing them. More 
significant, however, is the attention that has been committed to SARS-CoV and 
MERS-CoV since their emergence. 
 
SARS-CoV – First pandemic of the 21st century 
For over forty years after the discoveries of HCoV-OC43 and HCoV-229E, 
coronaviruses were considered only mildly important to human health. The 
discovery of SARS-CoV in 2003 and its rapid global spread dramatically changed 
this paradigm. The first indications that a new infectious threat had emerged 
came from reports of a large outbreak of atypical pneumonia in Guangdong 
Province, southern China, in November 2002 (39). This disease, termed severe 
acute respiratory syndrome (SARS) before its etiological agent had been 
identified, spread from Guangdong to Hong Kong, where a remarkable “super 
spreader” event took place on February 21, 2003 that led to large outbreaks in 
Canada, Vietnam, and Singapore (39-42). Ultimately, 8,096 cases and 774 
deaths were recorded in 27 countries by the time the outbreak was declared to 
be over on July 31, 2003 (43). 
 
Upon the recognition of a novel respiratory disease efforts began to 
identify the etiological agent and its source. By May 2003 three independent 
groups, in Hong Kong, Germany, and the United States (44-46) had identified a 
novel coronavirus as the likely cause of SARS. This determination was made 
based on morphology of the virus, partial genome sequencing, and virus isolation 
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in cell culture. The rapid identification of SARS-CoV and its receptor, angiotensin 
converting enzyme-2 (ACE-2) (47) would ultimately serve as a model for later 
studies that rapidly identified MERS-CoV and its cellular receptor. While the 
outbreak was still ongoing, numerous SARS-CoV isolates were fully sequenced 
and characterized (48, 49), representing one of the first examples of modern 
molecular biology being brought to bear against a novel infectious disease threat. 
 
Modern molecular biology techniques were combined with classic 
epidemiology to identify the source of the outbreak, a critical step in bringing it to 
an end. Experts quickly suspected that SARS-CoV was a zoonotic agent, 
transmitted from animals to humans. As early SARS-CoV cases were particularly 
common among restaurant workers who handled exotic game animals, 
suspicions about the source turned to live animal markets in southern China. 
SARS-CoV was isolated from palm civets and raccoon dogs in a single market, 
and there was a high prevalence of SARS-CoV antibodies found in animal 
handlers working in the same market (50). A second, and the last known SARS-
CoV outbreak at the end of 2003 provided further evidence for civet-to-human 
transmission, as employees and civets from the same restaurant were found to 
be infected with virtually identical SARS-CoV isolates (51). Although a strong link 
was drawn between civet and human SARS-CoV infections, extensive surveys 
failed to find SARS-CoV in civets outside animal markets, suggesting they were 
not the true wild reservoir (52), as did the observation that SARS-CoV infection of 
civets results in overt disease (53). Nevertheless, the live animal markets clearly 
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served to amplify transmission between civets and humans, and shutting down 
these markets was critical to ending the epidemic. 
  
Because various species of bat had previously been identified as 
reservoirs of zoonotic viruses such as Ebola (54), Marburg (55), Nipah (56, 57), 
and Hendra (57) viruses, they were also considered possible reservoirs of SARS-
CoV. A 2004 survey of more than 400 bats from four different regions of China 
found high seroprevalence and wide geographical distribution of anti-SARS-CoV 
antibodies in bats from the genus Rhinolophus, or horseshoe bats (58), as did a 
contemporary study conducted in Hong Kong (59).  Both reported the first full 
genome sequences of SARS-like coronaviruses (SL-CoVs), showing a much 
greater degree of genetic diversity among these viruses than among civet and 
human SARS-CoV isolates. Notably, the bat SL-CoV genomes have an intact 
ORF8, similar to civet and early human isolates, while later human isolates 
feature a 29 nucleotide deletion in this region (49, 50). 
 
Continued studies into the prevalence of SL-CoVs in Chinese bats has 
provided significant insight into the potential for a re-emergence of SARS-CoV or 
spillover of SL-CoVs into the human population. SARS-CoV is unusual among 
zoonotic viruses in that has not caused any additional human outbreaks, aside 
from a small cluster of cases in late 2003. However, SL-CoVs with the potential 
to infect humans continue to circulate among bat populations in China. In 2013 
the first bat SL-CoV that can infect human cells via ACE-2 was isolated from 
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Rhinolophus sinicus bats (60) and genome sequences of other viruses predicted 
to do were found in the same population. Serological evidence from humans in 
southern China suggests that SL-CoVs do infect humans (61) without erupting 
into large outbreaks. Whether these infections result in any clinical disease is 
unclear, but experimental evidence suggests that ACE-2 utilizing SL-CoVs, while 
capable of infecting human cells, may be less virulent than SARS-CoV (62, 63). 
The potential for SARS-CoV itself to re-emerge remains unclear. Unlike Marburg 
(64) or Nipah (56) viruses, SARS-CoV itself has not been found in a wild 
reservoir. The simplest explanation for why it has not re-emerged may be that it 
is extinct in the wild, and recent evidence suggests it arose due to a series of 
recombination events in a bat population rich with SL-CoVs (65) that may only 
rarely recombine to produce a virus with the potential to cause human outbreaks. 
Whatever the reason for the apparent disappearance of SARS-CoV, the diversity 
of SL-CoVs in the wild makes clear that the threat of such viruses remains, and 
the emergence of MERS-CoV in 2012 demonstrates that this threat is far from 
geographically isolated. 
 
Emergence and ecology of MERS-CoV 
For nearly a decade following the disappearance of SARS-CoV, 
coronaviruses receded as a public health concern. In September 2012 a novel 
coronavirus was isolated from a patient in the Kingdom of Saudi Arabia with fatal 
atypical pneumonia (66). Subsequently, infections by the same virus in Jordan 
were retrospectively identified dating to April 2012 (67). Rapid sequencing and 
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genomic characterization (68) of this virus quickly established that it was a novel 
betacoronavirus of lineage C (recently reclassified as Betacoronavirus subgenus 
Merbecovirus), most closely related to Asian bat coronaviruses that had been 
previously identified only by sequence (69). Subsequently, this virus was formally 
named Middle East respiratory syndrome-associated coronavirus (MERS-CoV). 
As of January 19, 2019 MERS-CoV has been responsible for 2,266 documented 
infections and 804 deaths, with the vast majority of these occurring in the 
Kingdom of Saudi Arabia, as well as a large travel-associated outbreak in the 
Republic of Korea (70). Like SARS-CoV, MERS-CoV causes severe disease 
primarily in older patients, with severe respiratory symptoms being the most 
common manifestation of documented infections (71). Also like SARS-CoV is the 
propensity of MERS-CoV to infect healthcare workers (72) and in fact the largest 
outbreaks have occurred in hospital settings. In contrast, and perhaps linked to 
its failure to cause a global pandemic, large MERS-CoV outbreaks in the 
community have not been documented, though unrecognized subclinical 
infections almost certainly occur (73). 
 
As with SARS-CoV, identifying the reservoir and source of MERS-CoV 
infections has been a major focus of research efforts since 2012. Due to the 
previous identification of related bat coronaviruses (69) and SL-CoVs in bats, it 
was quickly suspected that MERS-CoV originated in bats. A 2013 survey of bats 
in the vicinity of a small outbreak in Saudi Arabia recovered a small, 190 
nucleotide fragment with 100% identity to the MERS-CoV replicase gene in a 
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single bat (74). Though suggestive of a MERS-CoV bat reservoir, the fragment 
was isolated from just a single bat and no further evidence for MERS-CoV 
circulation in Arabian bats has emerged. Despite this early indication that MERS-
CoV might have a bat reservoir on the Arabian peninsula, a 2013 study from 
Ithete et. al. first suggested that bats from sub-Saharan Africa harbor viruses 
most closely related to MERS-CoV. This study identified an 816 nucleotide 
fragment from a South African Neoromicia capensis bat with 89.7% identity to the 
equivalent sequence from MERS-CoV (75). Characterization of the complete 
genome sequence of this virus showed 85% nucleotide identity to MERS-CoV 
across the entire genome with 97% amino acid identity, placing this virus 
(NeoCoV) in the same species as MERS-CoV (76). NeoCoV has recently been 
detected again in the wild (77) as has another virus (designated PREDICT/PDF-
2180) with a similarly close relationship to NeoCoV and MERS-CoV (78). 
 
Despite the overall close relationship of these viruses and MERS-CoV, the 
S1 subunit of the spike proteins of NeoCov and PREDICT/PDF-2180 that 
contains the receptor binding domain is highly divergent from that of MERS-CoV 
(79), and does not bind to or mediate infection of human cells (78). These 
findings support the hypothesis that, like SARS-CoV, MERS-CoV arose as a 
result of recombination events between different bat coronaviruses (76). Further 
supporting this hypothesis is the identification of currently circulating bat 
coronaviruses that can mediate entry into human cells using DPP4 (80-82). The 
spike protein of bat coronavirus HKU4 (BtCoV-HKU4) binds to human DPP4 and 
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can mediate entry when exogenous trypsin is added, suggesting the emergence 
of MERS-CoV may have required the acquisition of a DPP4-binding spike by a 
NeoCoV-like virus, as well as further adaptation in the fusion domain (80, 81). 
Later research has determined that two amino acid substitutions in the BtCoV-
HKU4 spike allow proteolytic processing of spike by human proteases and entry 
into human cells without the addition of trypsin (83). More recently, two MERS-
like bat coronaviruses identified in China show evidence of having acquired the 
S1 subunit of their spike proteins from HKU4-like viruses that bind human DPP4, 
providing further evidence for intra-spike recombination as essential in the 
emergence of MERS-CoV, and evidence that such events may not be particularly 
infrequent (82). 
 
Although these studies have illuminated the evolutionary history of MERS-CoV, 
the lack of an epidemiological link between bats and human infection suggested 
the possibility of an intermediate reservoir. Within a short period of the discovery 
of MERS-CoV, extensive serological surveys of Omani livestock identified a 
seroprevalence in dromedary camels of 100% (84). Similarly high 
seroprevalence and active MERS-CoV infection has been detected in dromedary 
camels across the Middle East, including Qatar (85), Egypt (86-88), the United 
Arab Emirates (89-91), Jordan (92), and Saudi Arabia (93, 94). By 2014, MERS-
CoV in camels had been convincingly linked to human outbreaks (85, 94-96). 
Continued studies have demonstrated that MERS-CoV isolates circulating in 
camels exhibit significantly greater genetic diversity than human isolates, 
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suggesting that camels are a source of human infection, rather than humans 
infecting camels (97-100). 
 
Further supporting the link between camels and human infection is 
growing evidence that intense exposure to camels is a significant risk factor for 
MERS-CoV infection. A 2015 nationwide serological survey in Saudi Arabia 
found an overall seroprevalence rate of 0.15% for anti-MERS-CoV antibodies, 
with camel shepherds being fifteen times and slaughterhouse workers twenty-
three times more likely to test positive than individuals without occupational 
exposure to camels (101). Notably, however, the low overall seropositive rate 
meant that although the total sample size was large (10,009 individuals) the 
absolute number of positive individuals was small (15, including just 2 shepherds 
and 3 slaughterhouse workers), leading the authors to call for a warranted 
degree of caution in interpretation. Despite the limitations of this particular study, 
it contributes to a compelling body of evidence that individuals with occupational 
exposure to camels are an entry point for zoonotic transmission of MERS-CoV 
into humans. One 2014 study of a human outbreak linked to a Qatari 
slaughterhouse found a high proportion of camels at the facility were actively 
shedding infectious virus (102), while another study in Qatar of a limited sample 
size found an elevated likelihood of seropositivity among workers with daily 
occupational exposure to camels (103). Additional serosurveys have further 
bolstered the link between occupational exposure to camels and human MERS-
CoV infection while also shedding light on an enduring mystery in the human 
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history of MERS-CoV; why a significant percentage of primary cases report no 
exposure to camels. A 2015 study identified two camel workers with active but 
asymptomatic MERS-CoV infection (104) and a 2018 study found that 50% of 
Saudi camel workers show evidence of previous MERS-CoV infection without a 
history of severe respiratory disease (105). The possibility of frequent 
asymptomatic infections among camel workers suggests a plausible route for 
MERS-CoV to enter the human population, where it may not be recognized until 
it causes severe disease, primarily in older individuals. 
 
Despite only being discovered recently, abundant evidence indicates that 
MERS-CoV has been circulating in Arabian camels for decades (93, 106, 107). 
While it remains unclear whether MERS-CoV infection of humans was 
unrecognized prior to 2012 or did not occur, the high camel seroprevalence in 
this region overlaps with the vast majority of known human infections. In addition 
to ubiquitous infection of dromedary camels on the Arabian peninsula, 
serosurveys of camels in sub-Saharan Africa have also demonstrated evidence 
of MERS-CoV infection dating back to at least 1983 (108-112). Contemporary 
studies continue to find evidence of widespread active dromedary infection in this 
expansive region (112). Despite this, no human MERS-CoV infections have been 
detected south of Egypt, and serosurveys produce evidence of only extremely 
limited human infection (113), even among individuals with extensive 
occupational exposure to camels positive for MERS-CoV RNA indicative of active 
infection (114). The absence of human MERS-CoV cases in Africa remains an 
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mystery which may be ascribed to genetic factors in potentially susceptible 
humans or genetic differences between African and Arabian MERS-CoV 
variants. There is a robust, unidirectional trade in dromedary camels from East 
Africa to the Arabian peninsula, but the MERS-CoV clades in these two regions 
appear to have diverged some time ago (115). The genetic diversity of African 
MERS-CoV variants coupled with the detection of the closest MERS-CoV 
relatives in sub-Saharan African bats suggests MERS-CoV first evolved in Africa 
and was introduced to the Arabian peninsula by imported camels, after which 
genetic drift may have given rise to variants with a greater ability to infect 
humans. Bolstering this hypothesis is a recent study that found African MERS-
CoV isolates replicate less robustly in both immortalized Calu-3 human airway 
epithelial cells and primary human respiratory tract ex vivo cultures compared to 
isolates from Saudi Arabia (116). Notably, the attenuation of these isolates was 
not linked to greater activation of antiviral immune responses, indicating genetic 
drift throughout the MERS-CoV genome may be responsible for its relatively 
emergence into humans. 
 
Coronavirus interactions with the OAS-RNase L antiviral pathway 
 
OAS-RNase L activation by viral dsRNA 
Like all viruses, coronaviruses employ mechanisms to evade, suppress or 
otherwise counteract host innate immune responses. The most important aspect 
of this response early in infection is the interferon (IFN)-dependent antiviral 
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response, which is triggered by host sensing of viral dsRNA. Without evasion or 
antagonism of this pathway, a virus is unlikely to establish a productive infection 
and replicate to a sufficient level that transmission to new hosts can occur. IFNs 
are a large class of 
cytokines, with type I (IFNα 
and IFNβ) and type III 
(IFNλ) IFNs being most 
critical for initiating innate 
antiviral immune 
responses (117, 118). 
Though both classes of 
IFNs induce expression of 
a similar suite of IFN 
stimulated genes (ISGs), 
IFNλ plays a dominant role 
at mucosal barriers such as the airway and intestinal tract (119, 120), where it is 
preferentially produced by and acts upon epithelial cells (121, 122). In the context 
of human coronavirus infections which primarily occur in the airway, IFNλ may 
therefore play a predominant role in the early antiviral response. 
 
The expression of these IFN genes occurs downstream of viral dsRNA 
sensing by host RIG-I-like receptors (Fig 1.2) (123, 124), specifically MDA5 in the 
context of coronavirus infection (125). Cytoplasmic dsRNA is a hallmark activator 
Figure 1.2 Major antiviral pathways induced by dsRNA. 
dsRNA activates three major classes of cytoplasmic pattern 
recognition receptors, The RIG-I like receptors (represented by 
MDA5, PKR, and OAS. MDA5 signals through the adaptor protein 
MAVS to induce phosphorylation of the transcription factor IRF3, 
which drives interferon gene expression. PKR activation results in 
auto-phosphorylation and phosphorylation of the translation 
initiation factor eIF2α, which arrests nascent protein synthesis. 
OAS proteins bind dsRNA and synthesize the second messenger 
2-5A, consisting of linear multimeric ATP molecules linked by 2’,5’ 
phosphodiester bonds. 2-5A binds RNase L monomers, inducing 
their dimerization and activation. 
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of the antiviral response because it is rare in uninfected cells or modified by the 
cellular adenosine deaminase ADAR1 such that it loses the capacity to activate 
antiviral signaling (126-128). IFN signaling induces the expression of up to 
several hundred ISGs, including other dsRNA binding proteins such as protein 
kinase R (PKR), and oligoadenylate synthetases (OAS), though high basal 
expression of PKR and OAS genes in some cell types allows their activation in 
the absence of additional IFN (129, 130). OAS proteins, upon binding dsRNA, 
catalyze the synthesis of a small second-messenger molecule 2’,5’-
oligoadenylate (2-5A) which binds to ribonuclease L (RNase L) monomers, 
inducing their dimerization and activation. Activated RNase L targets single-
stranded (ss) RNA of both cellular and viral origin and as such can have direct 
antiviral effects (131), cause translational arrest (132, 133), and lead to cell death 
(128). 
 
 Through the combination of these events downstream of its 
activation, RNase L can potently restrict the replication of diverse RNA and DNA 
viruses (131). These include flaviviruses such as West Nile virus (134, 135), 
hepatitis C virus (136), and Sindbis virus (SINV) (130). Consequently, numerous 
viruses encode well characterized antagonists of this pathway. These include 
dsRNA binding proteins such as E3L encoded by Vaccinia virus (VACV) (137) 
and the NS1 protein of influenza A viruses (138). Other known RNase L 
antagonists include the L* protein encoded by Theiler’s murine encephalomyelitis 
virus (139, 140) and the VACV D9 protein, an mRNA decapping enzyme (141). 
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The Weiss lab has extensively studied another class of OAS-RNase L 
antagonists, the host-derived phosphodiesterases (PDEs) encoded by select 
rotaviruses and, most significantly, by mouse hepatitis virus (MHV). 
 
OAS-RNase L antagonism by viral phosphodiesterases 
 As with many antiviral pathways, OAS-RNase L is vulnerable to 
evasion or antagonism at different points. While viruses such as Vaccinia and 
Influenza A use dsRNA binding proteins to prevent OAS activation, other viruses 
have acquired the ability to prevent RNase L 
activation downstream of OAS through 
cleavage of 2-5A (Fig 1.3). The prototypical 
viral protein acting by this mechanism is the 
MHV accessory protein NS2, which was first 
identified as a putative phosphodiesterase 
(PDE) in a 2002 computational analysis (142). 
Specifically, MHV NS2 belongs to a large 
family of phosphodiesterases called the LigT-
like 2H-phosphoesterases (2H-PE), named for 
the prototypical E. coli LigT protein, a 2’,5’ tRNA ligase, and characteristic 
catalytic HxS/Tx (x is typically a hydrophobic residue) motifs spaced 80-100 
residues apart (142-144). Although first identified in prokaryotes, 2H-PEs are 
ubiquitous throughout all three kingdoms of life and include numerous eukaryotic 
representatives. The 2H-PE central domain of mammalian A-kinase anchoring 
Figure 1.3 Viral antagonism of OAS-
RNase L. Viruses such as vaccinia and 
influenza A use dsRNA binding proteins 
E3L and NS1, respectively, to prevent 
dsRNA sensing by OAS proteins. Viral 
phosphodiesterases such as MHV NS2 
and rotavirus VP3, in contrast, degrade 
2-5A via 2’,5’ phosphodiesterase activity 
to prevent dimerization and activation of 
RNase L. 
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protein 7 (AKAP7) binds cAMP but the function of its catalytic activity remains 
unknown (145, 146), while USB1 has known exoribonuclease activity and 
processes the 3’ poly(U) tract of the U6 snRNA to protect it from exosomal 
degradation (147-151). Another eukaryotic 2H-PE, CGI-18, is a component of the 
large transcriptional co-activator complex Asc-1; its exact role in this complex 
remains undefined but may involve co-transcriptional or post-transcriptional RNA 
processing (142, 152, 153). 
 
 The Weiss laboratory has extensively studied 2H-PEs encoded by 
diverse RNA viruses that exhibit 2’,5’ phosphodiesterase (PDE) activity. The 
2002 computational analysis of 2H-PEs that identified the MHV NS2 accessory 
protein as a 2H-PE also identified an orthologous domain in the C-terminus of 
group A rotavirus (RVA) VP3 protein (142). An early study of MHV NS2 found 
that it was not essential for MHV replication in immortalized cell lines (154). 
However, a 2009 study found that mutation of either NS2 catalytic histidine 
(NS2H46A or NS2H126R) crippled viral replication in the liver though it did not impact 
MHV replication in the brain (155), suggesting NS2 inhibits a component of the 
antiviral response that is active in the liver but not the brain. Further work 
demonstrated that MHV-NS2H126R is attenuated in bone marrow-derived 
macrophages (BMMs) from wild-type (WT) B6 mice but replicates normally in 
BMMs generated from mice that lack expression of the type I IFN receptor 
(IFNAR) (156). Subsequent work demonstrated that MHV NS2 has specific 2’,5’ 
phosphodiesterase activity, enabling it to degrade 2-5A synthesized by OAS 
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proteins in response to viral dsRNA and linking the attenuation of MHV-NS2H126R 
explicitly to a failure to antagonize RNase L (157). 
 
 Work in the Weiss laboratory on the interaction of 2H-PEs with the 
OAS-RNase L pathway has extended beyond MHV NS2 to other viral and 
cellular members of the family. In a 2013 study the RVA VP3 C-terminal domain 
(CTD) 2H-PE, either WT or inactive VP3-CTDH798R was inserted in place of MHV 
NS4 in an MHV-NS2H126R background (158). In addition to exhibiting 2’,5’ PDE 
activity in biochemical assays, chimeric MHV-NS2H126R expressing RVA VP3-
CTD inhibited RNase L activation and replicated equivalently to WT MHV in 
BMMs. Additionally, VP3-CTD restored replication and pathogenesis of MHV-
NS2H126R in the mouse liver (158-160). A 2015 study confirmed that VP3 is 
involved in RNase L antagonism during bona-fide RVA infection (161). 
 
 In addition to this work on viral LigT-like 2H-PEs, the Weiss laboratory 
has investigated whether cellular homologs exhibit the same catalytic activity and 
have the potential to interact with the OAS-RNase L pathway. The central 
domain (CD) of long isoforms of AKAP7 contains a putative PDE domain with the 
expected HxS/Tx catalytic motifs. In biochemical assays the AKAP7 CD exhibits 
equivalent 2’,5’ PDE activity to MHV NS2, and like RVA VP3-CTD, can 
functionally replace NS2 in recombinant MHV-NS2H126R (162). Notably, the ability 
of AKAP7-CD to function in place of inactive NS2 required removal of its nuclear 
localization sequence (NLS), providing strong evidence that antagonism of 
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RNase L requires 2H-PEs be localized at least partly to the cytoplasm. This 
finding makes it unlikely that AKAP7 is involved in OAS-RNase L regulation in 
host cells. Rather, its exclusively nuclear localization (162) makes it more likely to 
participate in RNA processing like other cellular 2H-PEs. However, the 
observation that it has the same catalytic activity as MHV NS2 suggests that the 
ability to inhibit OAS-RNase L need not have been acquired through genetic drift 
of viral 2H-PEs after their acquisition from the host, but could have been present 
in the cellular ancestor. Following these findings, our work studying encounters 
between viruses and the OAS-RNase L pathway has continued. Additionally, we 
have expanded these studies to explore interactions between viral 2H-PEs and 
other arms of the innate antiviral response 
 
 This work has explored the function of viral 2H-PEs from diverse 
viruses within the order Nidovirales. In addition to MHV, other viruses within the 
subgenus Embecovirus (formerly lineage A) encode an NS2 protein that is a 
putative PDE, the lone exception being HCoV-HKU1. Although these NS2 
proteins are predicted to have similar structure and function to MHV NS2, it was 
unknown whether they exhibit the same ability to inhibit the activation of OAS-
RNase L. Chapter 3 of this thesis, published in 2016 in the Journal of Virology, 
describes our characterization of the interaction between 2H-PEs encoded by 
other embecoviruses, as well as a related torovirus, and the OAS-RNase L 
response (163). We found that in all but one case, the proteins we studied had 
equivalent enzymatic activity to MHV NS2 and were able to rescue replication of 
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MHV-NS2H126R. The lone exception, however, the NS2 protein of porcine 
hemagglutinating encephalomyelitis virus (PHEV), demonstrates that structure 
and function predictions 
are not sufficient for 
ascertaining biological 
activity. In the course of 
this study, we also 
identified the NS4b 
protein of MERS-CoV as 
a putative PDE and 
demonstrated that it too 
degrades 2-5A and 
inhibits RNase L 
activation by the same 
mechanism as MHV NS2 (Fig 1.4) (164). However, as described in Chapter 4, 
NS4b localizes primarily to the nucleus unlike other viral 2H-PEs, which spurred 
us to investigate additional functions. Due to this continuation of our work, we 
have demonstrated that in addition to inhibiting the OAS-RNase L pathway, 
MERS-CoV NS4b also inhibits the interferon response, as IFN and other antiviral 
transcripts are more abundant during infection with recombinant MERS-CoV 
containing targeted mutations in the NS4b catalytic site or nuclear localization 
sequence (Fig 1.4) (165). Although the specific mechanism of NS4b interaction 
with the IFN response remains unclear, it is clear that this work has uncovered 
Figure 1.4 Viral PDE interactions with the innate immune 
response. A) PDEs encoded by MHV-like betacoronaviruses 
(OC43, ECoV, HECoV), torovirus strain Berne (BEV), and MERS-
CoV inhibit activation of RNase L through cleavage of the 2-5A 
second messenger produced by OAS. B) MERS-CoV NS4b 
suppresses the abundance of antiviral mRNAs, with IFN and ISG 
transcript increasing in abundance in the context of mutant NS4b. 
IRF3 nuclear translocation is unaffected by mutation of NS4b, 
indicating the interaction likely occurs downstream of this point, 
while the specific underlying mechanism remains unknown. 
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previously unrecognized interactions between viral 2H-PEs and host antiviral 
responses. Continued work in the Weiss laboratory will include a focus on 
elucidating the mechanistic nature of these interactions.  
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Abstract 
Viruses in the family Coronaviridae, within the order Nidovirales, are etiologic 
agents of a range of human and animal diseases, including both mild and severe 
respiratory disease in humans. These viruses encode conserved replicase and 
structural proteins, and more diverse accessory proteins in the 3’ end of their 
genomes that often act as host cell antagonists. We have previously shown that 
2’,5’ phosphodiesterases (PDE) encoded by the prototypical Betacoronavirus, 
mouse hepatitis virus (MHV) and Middle East respiratory syndrome-associated 
coronavirus (MERS-CoV) antagonize the oligoadenylate synthetase – 
ribonuclease L (OAS-RNase L) pathway. Here we report that additional 
coronavirus superfamily members including lineage A betacoronaviruses and 
toroviruses infecting both humans and animals encode 2’,5’ PDEs capable of 
antagonizing RNase L. We used a chimeric MHV system, in which exogenous 
PDEs were expressed from an MHV backbone lacking a functional NS2 protein 
(MHVMut), its endogenous RNase L antagonist to test the ability of these PDEs to 
antagonize RNase L. In this system, we found that 2’,5’ PDEs encoded by 
human coronavirus HCoV-OC43 (OC43), an agent of the common cold, human 
enteric coronavirus (HECoV), equine coronavirus (ECoV), and equine torovirus-
Berne (BEV) are enzymatically active, rescue replication of MHVMut in bone 
marrow-derived macrophages and inhibit RNase L-mediated rRNA degradation 
in these cells. Additionally, PDEs encoded by OC43 and BEV rescue MHVMut 
replication and restore pathogenesis in WT B6 mice. This finding expands the 
range of viruses known to encode antagonists of the potent OAS-RNase L 
 49 
antiviral pathway, highlighting its importance in a range of species, as well as the 
selective pressures exerted on viruses to antagonize it. 
 
Importance 
Viruses in the family Coronaviridae include important human and animal 
pathogens, including the recently emerged SARS-CoV and MERS-CoV. We 
have shown previously that two viruses within the genus Betacoronavirus, mouse 
hepatitis virus (MHV) and MERS-CoV, encode 2’,5’ phosphodiesterases (PDEs) 
that antagonize the OAS-RNase L pathway and report here that these proteins 
are furthermore conserved among additional coronavirus superfamily members 
including lineage A betacoronaviruses and toroviruses, suggesting they may play 
critical roles in pathogenesis. As there are no licensed vaccines or effective 
antivirals against human coronaviruses and few against those infecting animals, 
identifying viral proteins contributing to virulence can inform therapeutic 
development. Thus, this work demonstrates that a potent antagonist of host 
antiviral defenses is encoded by multiple and diverse viruses within 
Coronaviridae, presenting a possible broad-spectrum therapeutic target.   
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Introduction 
Coronaviruses (CoV) and closely related toroviruses (ToV) are well known 
agents of disease in mammals, including humans. Coronaviruses and 
toroviruses, members of the family Coronaviridae within the order Nidovirales, 
contain positive sense single stranded (ss)RNA genomes ranging from 28-31 
kilobases in length, among the longest known RNA genomes (1-3). The first two 
thirds of their genomes encode the replicase proteins, which include the viral 
RNA-dependent RNA polymerase and numerous non-structural proteins (NSPs), 
which are required for replication and in some cases have host immune 
antagonist activities (4). The structural proteins are encoded in the 3’ third of the 
genome and consist of spike (S), small membrane protein (E), membrane (M), 
nucleocapsid (N) and sometimes hemagglutinin-esterase (HE). Interspersed 
among the structural genes are diverse genes encoding accessory proteins that 
are not essential for replication but are believed to be required for virulence in 
vivo (1). 
 
Mouse hepatitis virus (MHV) is a lineage A Betacoronavirus and the 
prototypical CoV. MHV encodes the accessory protein NS2 which was previously 
identified as a 2-His (H) phosphoesterase (2H-PE) superfamily member (5), and 
that we have demonstrated has 2’,5’-phosphodiesterase (PDE) activity that 
antagonizes the host 2’,5’-oligoadenylate synthetase (OAS)-ribonuclease 
(RNase) L pathway (6). Upon sensing double stranded (ds)RNA, OAS proteins 
synthesize 2’,5’-oligoadenylates (2-5A) which catalyze the activation of RNase L 
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via homodimerization. RNase L subsequently cleaves host and viral ssRNA 
leading to termination of protein synthesis and subsequent apoptosis (7). NS2 
cleaves 2-5A thus preventing the activation of RNase L.  NS2 is a critical 
determinant of MHV strain A59 (A59) liver tropism in C57BL/6 (B6) mice and is 
required for the virus to cause hepatitis.  Mutant MHV A59 (MHVMut) expressing 
NS2 with an inactive phosphodiesterase domain (NS2H126R) is unable to 
antagonize the OAS-RNase L pathway in mouse bone marrow-derived 
macrophages (BMMs) or the mouse liver. Infection with this virus does not result 
in hepatitis and MHVMut replication is reduced at least 10,000 fold compared to 
wild-type (WT) MHV A59. However, in mice genetically deficient for RNase L 
(RNase L-/-), MHVMut replicates to wild-type levels and causes hepatitis (6). 
 
As might be expected of antagonists of a potent innate antiviral pathway, 
2’,5’ PDEs are not a host evasion mechanism unique to MHV. We recently 
showed that the NS4b accessory protein of MERS-CoV and related bat 
coronaviruses, all lineage C betacoronaviruses, exhibit 2’,5’-PDE activity (8). 
Additionally, unrelated group A rotaviruses encode a PDE in the C-terminal 
domain of the VP3 structural protein (9). We show here that lineage A 
betacoronaviruses closely related to MHV, including the human respiratory 
HCoV-OC43 (OC43), human enteric CoV-4408 (HECoV), equine ECoV-NC99 
(ECoV), and porcine hemagglutinating encephalomyelitis virus (PHEV), as well 
as the more distantly related equine torovirus (EToV)-Berne (BEV) also encode 
NS2 homologs with predicted PDE activity. We found that these proteins do 
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possess enzymatic 2’,5’-PDE activity that is capable of antagonizing RNase L 
(with the exception of PHEV NS2) and thus countering a potent host antiviral 
response, suggesting that PDE mediated OAS-RNase L antagonism is an 
important virulence strategy for lineage A betacoronaviruses and toroviruses. 
 
Material and Methods 
 
Cell lines and mice. Murine fibroblast L2 (L2), murine 17 clone 1 (17Cl1) and 
baby hamster kidney cells expressing MHV receptor (BHK-R) were cultured as 
previously described (10, 11). C57BL/6 (B6) mice were originally procured from 
the National Cancer Institute mouse repository, and RNase L-/- mice on a B6 
genetic background were derived by Dr. Robert Silverman (12) and subsequently 
bred in the University of Pennsylvania animal facility.  All experiments involving 
mice were approved by the Institutional Animal Care and Use Committee at the 
University of Pennsylvania.  Primary bone marrow-derived macrophages (BMM) 
were generated from marrow harvested from the hind limbs (tibia and femur) of 
four to six week old B6 or RNase L-/- mice as described previously (6, 13). Cells 
were cultured in DMEM (Gibco) supplemented with 10% FBS (Hyclone) and 20% 
L929 cell-conditioned media for 6 days before infection. 
 
Plasmids. NS2 genes from lineage A betacoronaviruses OC43, HECV-4408, 
ECoV-NC99 NC99, PHEV and pp1a-carboxyterminal domain (CTD) from the 
torovirus Berne were synthesized and cloned into pUC57 by BioBasic yielding 
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pUC-OC43NS2, pUC-HECVNS2, pUC-ECoVNS2, pUC-PHEVNS2 and pUC-
pp1a. The second catalytic His to Arg substitutions were made by site directed 
mutagenesis in all plasmids resulting in pUC-OC43-NS2H129R, pUC-HECV-
NS2H129R, pUC-NC99-NS2H129R, pUC-PHEV-NS2H129R and pUC-pp1aH4516R. 
Select genes were subsequently sub-cloned into the pMal parallel-2 expression 
vector resulting in pMAL-OC43-NS2, pMAL-OC43-NS2H129R, pMAL-PHEV-NS2, 
pMAL-PHEV-NS2H129R, pMAL-pp1a and pMAL-pp1aH4516R.  MHV NS2 and 
NS2H126R had been previously cloned into pMAL-c2 (6). 
 
Purification of recombinant PDEs from E. coli and FRET assay. MBP-PDE 
fusion proteins were expressed from pMAL-plasmids in BL21 T7 expression 
competent E. coli (NEB, Inc., Ipswich, MA) and purified by affinity 
chromatography followed by ion exchange chromatography on MonoQ GL10/100 
using a NaCl gradient from 0 to 1 M in 20 mM NaCl as previously described (6, 
14). The integrity and the purity of the purified MBP fusion proteins were 
determined by SDS-PAGE electrophoresis and Coomassie Blue R250 staining. 
The extent of purity was similar for all of the enzymes as assessed by SDS-
PAGE analysis. To assess enzymatic activity, purified proteins  [10 µM MBP (420 
µg/ml) as control or 1 µM OC43 (75 µg/ml);  BEV (60 µg/ml) PHEV (65 µg/ml) or 
MHV (70µg/ml) MBP-PDE fusion proteins] in 150 µl of assay buffer (20 uM 
HEPES [pH 7.2], 10 mM MgCl2, 1 mM dithiothreitol) were incubated at 30° with 
(2’-5’)p3A3 (2-5A). After one hour, reactions were stopped by heat inactivation at 
95° for 3 min followed by 30 min centrifugation at 20,000 X g (4°) and 
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supernatants carefully removed. A fluorescent resonance energy transfer (FRET) 
assay was used to assess enzymatic activity by measuring the amount of 
uncleaved, intact 2-5A left in the reaction, as previously described (15). The 
abilities of recombinant enzyme to degrade 2-5A were determined by a FRET 
based RNase L activation assay using an authentic 2-5A (2’,5’-p3A3) trimer as 
described earlier (6, 8, 16, 17). Assays were performed three times in triplicate 
using two separate enzyme preparations. 
 
Viruses and chimeric recombinant virus construction. Wild-type MHV strain 
A59 and mutant NS2H126R (referred to as MHV and MHVMut in the data shown 
herein) were described previously (6, 9). The chimeric viruses were constructed 
based on the infectious cDNA clone icMHV-A59 (10, 18). The wild-type and 
mutant PDEs genes were PCR amplified from the pUC plasmids constructed 
above with primers bearing SalI and NotI restricting sites. After purification and 
digestion with SalI and NotI, the fragments were cloned into icMHV-A59 fragment 
G, with an NS2H126R mutation, as previously described (9) and confirmed by DNA 
sequencing. The full-length A59 genome cDNA was assembled, and the 
recombinant viruses were recovered in BHK-R cells as previously described (9, 
10, 17, 18). When virus cytopathology was observed, virus was plaque purified 
from the supernatant and amplified on 17CL-1 cells for use.  The pairs of 
chimeric viruses expressing WT and mutant PDEs were named by the source of 
the PDE, OC43 & OC43Mut, HECoV & HECoVMut, PHEV & PHEVMut, ECoVMut & 
ECoV and BEV & BEVMut. The PDE gene and flanking regions were amplified by 
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PCR from the cloned chimeric virus genomes and the sequences verified. The 
primers used for sequencing were Fns4 (5’-
TTGTTGTGATGAGTATGGAG)  which maps 136 nucleotides upstream of the 
ATG start codon for the PDE and Rns4 (5’-GCGTAACCATGCATCACTCAC) 
which maps 139 nucleotides downstream of the PDE ORF The regions 
sequenced include the SalI and NotI restriction sites as well as the transcription 
regulatory sequence (TRS) for ORF4 and ORF5a. 
 
Chimeric MHV infections of bone marrow derived macrophages (BMM). 
BMMs were mock infected or infected at a multiplicity of infection (MOI) of 1 
PFU/cell (in triplicate) and allowed to adsorb for 1 hour at 37 °C. Cultures were 
washed with PBS (3 times) and fed with medium. At the times indicated, cells 
were lysed and analyzed for degradation of RNA (described below) or 
supernatants were harvested for quantification of viral titers by plaque assay on 
L2 cells (6, 9). 
 
Immunoblotting. L2 cells were infected with MHV or chimeric viruses (MOI=1 
PFU/cell). At 10 hours post-infection, cells were lysed in nonidet P-40 (NP-40) 
buffer (1% NP-40, 2 mM EDTA, 10% glycerol, 150 mM NaCl and 50 mM Tris pH 
8.0) containing protease inhibitors (Roche). Protein concentrations were 
measured using a DC protein assay kit (Bio-Rad). Supernatants were mixed 3:1 
with 4X SDS-PAGE sample buffer. Samples were boiled, separated by 4-15% 
SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. 
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Blots were blocked with 5% nonfat milk and probed with the following antibodies: 
anti-Flag M2 mouse monoclonal antibody (Agilent, 1:1000); anti MHV 
nucleocapsid mouse monoclonal antibody (a gift from Dr. Julian Leibowitz; 1:400) 
and anti GAPDH mouse monoclonal antibody (Thermo Scientific, 1:1000). Anti-
mouse HRP (Santa Cruz; 1:5000) secondary antibodies were used to detect the 
primary antibodies. The blots were visualized using Super Signal West Dura 
Extended Duration Substrate (Thermo Scientific). Blots were probed sequentially 
with antibodies with stripping between antibody treatments. 
 
Analysis of RNase L mediated rRNA degradation. RNA was harvested from 
B6 WT BMMs infected with MHV and chimeric viruses encoding WT and 
catalytically inactive PDEs at the indicated time points using a Qiagen RNeasy 
kit. RNase was denatured at 70° for 2 min and analyzed with an Agilent 
BioAnalyzer 2100 on a eukaryotic total RNA nanochip. The BioAnalyzer converts 
the electropherogram generated for each sample into the pseudogel as depicted 
in Fig 2.6 (6). 
 
Replication in mice. Four week old B6 or RNase L-/- mice (5-7) were 
anesthetized with isoflurane (Abbott Laboratories; Chicago, IL) and inoculated 
intrahepatically with 2000 PFU in 50 μL of DPBS (Gibco) containing 0.75% 
bovine serum albumin (Sigma). Mice were euthanized with CO2, perfused with 
DPBS (Gibco) and livers harvested at day five post inoculation.  Part of the liver 
was fixed for histology and the rest was homogenized and viral titers were 
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determined by plaque assay of liver homogenates on L2 cells (19). A piece of 
each liver was fixed overnight in 4% paraformaldehyde, embedded in paraffin 
and sectioned. Sections were stained with hematoxylin and eosin (H&E) or 
alternatively blocked with 10% normal donkey serum and immunostained with a 
1:20 dilution of a monoclonal antibody against MHV nucleocapsid (N) protein 
(1:1000 dilution). Staining was developed using avidin-biotin-immunoperoxidase 
(Vector Laboratories). 
 
Results 
 
Alignment and modeling of coronavirus and torovirus NS2 proteins. To 
determine whether the MHV-related betacoronaviruses encode proteins with 
2’,5’-PDE activity we first analyzed the primary amino acid sequence of the NS2 
proteins from OC43, HECoV, ECoV-NC99, PHEV and the pp1a-CTD of BEV. 
While the NS2 homologs are encoded within ORF2, the PDE of BEV is encoded 
at the 3’ end of the ORF1a and processed from the pp1a polyprotein (4). All of 
these proteins contain two conserved HxS/Tx motifs spaced by ~80 residues, 
where x is any hydrophobic residue, characteristic of 2H-phosphoesterase 
superfamily proteins (5, 6, 9) (Fig 2.1).  Interestingly the carboxytermini of the 
PHEV and BEV PDEs are truncated relative to the other NS2 proteins, similar to 
the group A rotavirus VP3-CTD PDE (9, 25, 26). We further entered the primary 
amino acid sequence of these proteins into Phrye2 to predict their tertiary 
structures (Fig 2.2). All of these proteins scored highly for homology with the 
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published structure of the A-kinase anchoring protein 7 (AKAP7) central domain 
(CD) (27), a 
previously 
identified host-
encoded 2H-PE 
with 2’,5’-PDE 
activity (17). We 
have previously 
shown that the 
MHV NS2 and 
group A rotavirus 
(RVA) VP3 
proteins, also structural homologs of AKAP7 CD, exhibit 2’,5’ PDE activity and 
can antagonize RNase L (6, 9, 17). 
 
Coronavirus and torovirus putative 2’,5’ PDEs are enzymatically active and 
cleave 2-5A. To determine whether the predicted nidovirus PDEs (OC43 NS2, 
BEV pp1a-CTD, PHEV NS2) are enzymatically active, the genes encoding them 
as well as their corresponding mutants with an Arg substitution of the second 
predicted catalytic His residue were expressed in Escherichia coli as maltose 
binding protein (MBP) fusion proteins and purified by affinity chromatography 
followed by ion exchange chromatography and size exclusion chromatography 
as described in Materials and Methods (6). Purified wild type or catalytic mutant 
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Figure 2.1. Alignment of lineage A betacoronavirus  and Berne torovirus PDEs.  
PDEs with Genbank accession numbers are MHV NS2 (P19738.1) (20), OC43 NS2 
(AAT84352.1) (21), HECoV NS2 (ACJ35484.1),   ECoV NS2 (ABP87988.1) (22), 
PHEV NS2 (AAY68295.1) (23) and BEV (CAA36600.1) (24). Conserved catalytic 
HxS/Tx motifs are indicated by boxes. Contributor: JMT 
 
 59 
proteins were incubated with 2-5A substrate and an indirect fluorescent 
resonance energy transfer (FRET) assay was used to assess activation of 
RNase L, in which higher RLUs represent active RNase L as described in 
Materials and Methods and in detail previously (15). MHV NS2 was utilized as a 
positive control for inhibition of 
RNase L (Fig 2.3).  OC43 and BEV 
proteins reduced RNase L activation 
to a similar degree as MHV NS2, 
while PHEV NS2 was significantly 
less active. The mutant proteins 
containing a His à Arg mutation in 
the second catalytic motif did not inhibit RNase L, as expected and consistent 
with previously results describing MHV NS2 (6). 
 
Coronavirus and Torovirus PDEs 
inhibit RNase L when expressed 
from a chimeric MHV NS2 mutant 
backbone. To investigate whether 
the NS2 proteins of OC43, HECoV, 
ECoV, PHEV, and BEV pp1a-CTD 
can antagonize RNase L during 
infection, we constructed chimeric 
viruses expressing each exogenous 
A B C
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S4443
T4518
H4516
S48
T128
H126
H46 H4441
MHV OC43 BEV
Figure 2.2. Known and predicted structures of 
nidovirus PDEs. (A) Crystal structure of MHV NS2 
(PDB: 4Z5V) and predicted structures of OC43 NS2 
(B) and BEV pp1a-CTD (C). Predicted structures 
were generated using Phyre2 then visualized and 
annotated using UCSF Chimera 1.8. Catalytic His 
and conserved Ser/Thr residues are indicated. 
Contributors: JMT and SAG 
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Figure 2.3. PDE activity assay of coronavirus and 
torovirus PDEs. Recombinant WT and mutant PDEs  
were incubated with 2-5A for 60 minutes and the 
remaining substrate was quantified using an indirect 
FRET based assay as described in Materials and 
Methods.  RFU= relative fluorescence units, is 
proportional to 2-5A remaining. Data shown are from 
one representative of three independent experiments, 
each carried out in triplicate with separate enzyme 
preparations and are expressed as means ± SEM; *, P 
< 0.05, **, P < 0.01, ***, P < 0.001. Contributors: BKJ 
and JMT 
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PDE from ORF4 (encoding NS4a, 4b) of an MHV backbone (Fig 2.4).  The MHV-
A59 backbone we utilized encodes 
the H126R substitution in NS2 
(MHVMut, referred to in literature as 
NS2H126R) that abrogates its 
enzymatic activity and ability to 
antagonize RNase L. MHVMut exhibits 
minimal replication in primary bone 
marrow-derived macrophages (BMM) 
or in vivo (6). The chimeric viruses 
we constructed express either the 
exogenous PDE protein or its 
catalytic mutant from the ORF4 locus 
of MHV, which is dispensable for 
MHV replication in vitro and in vivo (28). Each exogenous protein was 
constructed with a C-terminal Flag-tag to allow verification of expression from the 
chimeric viruses. To assess expression of PDEs by western blot, we infected L2 
cells with the chimeric viruses and harvested protein lysates 10 hours post-
infection (hpi). We probed for the exogenous PDEs using a primary antibody 
directed against the Flag-tag, and utilized GAPDH as a loading control (Fig 2.5). 
The OC43, HECV and ECov PDEs were detectable by western blot at a high 
level of abundance, while detection of BEV pp1-CTD expression was less robust. 
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OC43 NS2Mut 
49 129 
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H
H
1a 1b NS4 5a 
E M I N 
MHV  
NS2 
NS2Mut NS4 
OC43 NS2 
ECoV NS2 
HECoV NS2 
PHEV NS2 
BEV pp1a-CTD 
 NS2
Mut 
NS2Mut 
OC43 NS2Mut 
ECoV NS2Mut 
HECoV NS2Mut 
PHEV NS2Mut 
BEV pp1a-CTDMut 
 
Figure 2.4. NS2 organization and construction of 
chimeric viruses. (A) Depiction of the NS2 protein of 
HCoV-OC43. Shown are the catalytic His residues at 
positions 49 and 129, with the His->Arg mutation 
shown below. (B) Genome organization of MHV with 
NS2 and NS4 loci indicated. Also shown are replicase 
open reading frames 1a and 1b, genes encoding 
structural proteins HE, S, E, M, N and I as well as 
nonstructural protein 5a.  In chimeric viruses MHV NS2 
residue 126 is mutated from H->R, rendering NS2 
catalytically inactive  (NS2Mut). The gene encoding the 
exogenous PDE or its catalytically inactive mutant is 
inserted in place of MHV NS4. Contributor: SAG 
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PHEV NS2 expression from multiple viral clones as well as the swarm of 
uncloned recombinant virus could not be detected by western blot. 
 
Exogenous coronavirus and torovirus PDEs rescue replication of MHV
Mut
 in 
primary B6 BMMs through inhibition of RNase L activation. To determine if 
the exogenous PDEs can antagonize RNase L in the context of infection, we 
infected BMMs from WT B6 
and RNase L-/- mice with 
MHV, MHVMut and the 
chimeric viruses and 
measured replication by 
plaque assay at 6, 9, 12, and 
24 hpi. As expected, MHVMut  
is significantly attenuated in 
WT BMMs but replicates to 
equivalent titers as MHV in 
RNase L-/- BMMs (Fig 2.6A). All of the chimeric viruses encoding WT exogenous 
PDEs from OC43, HECoV, ECoV and BeV, replicated to a similar extent as WT 
A59 in B6 BMMs, indicating that these proteins effectively compensate for an 
inactive NS2H126R in MHV (Fig 2.6B-E).  In contrast, and similarly to MHVMut, the 
chimeras expressing catalytically inactive exogenous PDEs fail to replicate 
robustly in B6 BMMs but do replicate efficiently in RNase L-/- BMMs (Fig 2.6A-E).  
Flag	
N	
GAPDH	
OC43	 HECV	 PHEV	 ECoV	 BEV	MHV		
WT	 mut	 WT	 mut	WT	 mut	WT	 mut	WT	 mut	WT	 mut	
Mock	
Figure 2.5. Expression of exogenous PDEs from chimeric 
viruses. L2 cells were infected with MHV or chimeric viruses and 
protein harvested 10 hpi and analyzed by western immunoblotting.  
Blots were probed with  antibody against Flag to detect PDEs, anti-
nucleocapsid  antibody to assess chimeric viral infection and GAPDH 
as a protein loading control. MHV NS2 (lanes 1-2) is not Flag-tagged. 
Flag-tagged WT and mutant PDEs of OC43, HECV, PHEV, ECoV 
and BEV are detected as indicated. This blot was performed two 
times using proteins from independent infections with similar results. 
Contributor: JMT 
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The chimeric virus encoding PHEV NS2 were not assessed for replication in 
BMMs due to our inability to confirm its expression (Figure 2.5).  
To directly link antagonism of 
RNase L to the ability of the 
exogenous PDEs to rescue 
MHVMut replication, we assessed 
rRNA degradation in infected 
cells by Bioanalyzer. We have 
previously used this assay to 
demonstrate that MHV NS2, but 
not NS2H126R, inhibits RNase L-
mediated RNA degradation, and 
that a deficiency in RNase L 
obviates the requirement for 
NS2 in MHV replication (6). We 
infected B6 WT and RNase L-/- 
BMMs with MHV and the 
chimeric viruses and harvested 
total RNA 9 hpi. We ran the total RNA on a Bioanalyzer to visualize the integrity 
of rRNA during infection with MHV and the chimeric viruses. MHV and the 
chimeric viruses encoding exogenous PDEs encoded by MHV, OC43, HECoV, 
ECoV and BEV prevented rRNA degradation in B6 WT BMMs, while the 
corresponding catalytically inactive PDEs failed to do so (Fig 2.6F). This directly 
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Figure 2.6. Replication and activation of RNase L by 
chimeric viruses in bone marrow derived macrophages 
(BMM). (A-E) BMMs derived from WT B6 or RNase L-/- mice 
were infected with (A) MHV  or chimeric MHV viruses 
expressing WT or mutant (B) OC43 NS2, (C) HECoV NS2, (D) 
ECoV NS2 and (E) BEV pp1a-CTD.  Virus at each time point 
was titrated by plaque assay. Each time point is represented 
by three biological replicates, titrated in duplicate and variance 
expressed as SEM. Statistical significance was calculated by 
2-way ANOVA in GraphPad Prism. **, P <0.01; ***, P <0.001. 
(F) Total RNA was isolated from WT B6 BMMs 9 hpi and rRNA 
integrity assayed using an Agilent BioAnalyzer. These data are 
from one of at least two independent experiments with similar 
results. Contributors: JMT, RZ, RE, SAG, and YL 
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links the ability of the exogenous PDEs to rescue MHVMut replication to their 
antagonism of RNase L activation. 
 
OC43 NS2 and BEV pp1a-CTD restore MHV
Mut
 replication and pathogenesis 
in vivo. MHV causes profound hepatitis and associated liver pathology in B6 
mice, with its liver replication and pathogenesis dependent on NS2-mediated 
antagonism of RNase L (Fig 2.7) (6). To determine whether exogenous viral 
PDEs can rescue replication and restore pathogenesis to MHVMut, we infected B6 
and RNase L-/- mice with MHV, MHVMut and the chimeric viruses expressing 
either WT or catalytic mutant PDEs from OC43 (NS2) and BEV (pp1a-CTD). Five 
days post-infection, at the time of peak 
titer, the mice were sacrificed and 
livers harvested for virus titration by 
plaque assay. In WT B6 mice chimeric 
viruses expressing either WT OC43 
NS2 or BEV pp1-CTD replicated 
robustly in the liver, similarly to MHV. 
In contrast, and like MHVMut, the 
chimeric viruses expressing 
mutant OC43 NS2 (Fig 2.7B) 
or BEV pp1a-CTD (Fig 2.7C) 
are dramatically restricted, 
replicating only to titers below 
Figure 2.7. Replication and pathogenesis of chimeric 
viruses in vivo. (A-C) WT B6 or RNase L-/- mice (n= 5-7) were 
infected intrahepatically with (A) MHV and MHVMut or chimeric 
viruses encoding WT or mutant (B) OC43 NS2 or (C) BEV pp1a-
CTD. Five days post-infection livers were harvested and virus 
titrated by plaque assay. Each data point represents a single 
mouse liver, titrated in duplicate with variance expressed as 
SEM. Statistical significance determined by 1-way ANOVA in 
GraphPad Prism. ***, P <0.001. Liver sections from infected mice 
were stained with (D) H&E to identify hepatic pathology or (E) 
antibody to detect MHV nucleocapsid protein. Contributors: 
JMT, RZ, RE, and SAG 
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or just above the limit of detection, whereas all of the chimeric viruses replicated 
robustly in the livers of RNase L-/- mice (Fig 2.7A-C).  To assess hepatitis in these 
infected mice, liver sections were assessed for viral antigen and pathological 
changes. Like A59, chimeric viruses expressing WT OC43 NS2 or BEV pp1a-
CTD caused hepatitis in B6 mice, indicated by pathologic foci in H&E stained 
livers, with viral antigen staining widely observed (Fig 2.7D,E).  Chimeric viruses 
expressing catalytically inactive OC43 NS2 or BEV pp1a-CTD did not cause liver 
pathology in B6 mice and viral antigen was absent, consistent with the lack of 
replication (Fig 2.7D,E). In RNase L-/- mice, all of the chimeric viruses replicated 
robustly and caused pathology similar to MHV A59 (Fig 2.7D,E), further 
demonstrating that the restriction of the viruses expressing mutant PDEs in B6 
mice is RNase L-mediated and that the exogenous PDEs function equivalently to 
MHV NS2. 
 
Discussion 
We have previously demonstrated 2-5A cleavage and RNase L 
antagonism by 2’,5’ PDEs encoded by a lineage A and a lineage C 
betacoronavirus (MHV and MERS-CoV respectively) and group A rotaviruses as 
well as by cellular AKAP7 CD (6, 8, 9, 17). Here, we extend these findings to 
show that additional lineage A betacoronaviruses as well as a related torovirus 
family member encode 2’,5’ PDEs capable of antagonizing RNase L by cleaving 
2-5A. The presence of genes encoding these proteins in  multiple lineage A 
betacoronaviruses suggests that this gene was acquired by an ancient common 
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ancestor of this lineage. Whether this virus was also ancestral to toroviruses and 
lineage C betacoronaviruses, or whether 2’,5’ PDEs were acquired by viruses in 
multiple independent events is unclear. The maintenance of this highly 
conserved protein throughout lineage A betacoronaviruses supports the idea that 
this protein mediates an essential function in the diverse natural hosts of these 
viruses, spanning multiple mammalian families. Our finding of a homologous 
PDE in some groups of rotaviruses (9), a virus family unrelated to coronaviruses 
is intriguing. A coronavirus recently isolated from bats was found to encode a 
protein likely to have originated from a bat orthoreovirus, which like rotaviruses 
has a dsRNA genome, suggesting the possibility of recombination between 
coronaviruses and a dsRNA virus (29).  Further support for this idea comes from 
a recent report of isolation of a MERS-like coronavirus and a rotavirus in the 
feces of Korean bats (30). Additionally, the viruses encoding the PDEs we have 
described here infect different tissues within their hosts (1, 31, 32), indicating that 
RNase L antagonism may be required for robust replication in diverse cell types. 
For example, although MHV is hepatotropic, OC43 infects the upper airway, 
while other PDEs described here are encoded by enterotropic viruses (1, 31, 32). 
 
The PDEs encoded by OC43, HECoV, ECoV and BEV antagonized 
RNase L and rescued replication of MHVMut in primary WT B6 BMMs, indicating 
that not only are they enzymatically active 2’,5’ PDEs, but that they functionally 
compensate for an inactive MHV NS2 (Fig 2.3, 2.6, 2.7). Interestingly the BEV 
encoded PDE was able to antagonize RNase L and rescue MHVMut replication 
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both in vitro and in vivo despite the apparently low level of expression (Fig 2.5, 
2.6, 2.7). This is not entirely surprising as the MERS-CoV NS4b PDE can rescue 
MHVMut despite its low abundance in the cytoplasm (8). PHEV NS2 is less 
enzymatically active than the other PDEs (Fig 2.3), suggesting it may be less 
able to antagonize RNase L. However, since we could not detect expression by 
western blot of the PHEV PDE from a chimeric virus (Fig 2.5), further work will be 
needed to determine if it has RNase L antagonist activity in the context of 
infection. Interestingly both the BEV and PHEV PDEs are truncated at the 
carboxytermini similar to the rotavirus PDE (Fig 2.3) (9); clearly the 
carboxyterminal sequences are not required for cleavage of 2-5A or RNase L 
antagonism as the rotavirus VP3-CTD and BEV PDEs have similar activity to 
MHV NS2 (Fig 2.3) (9). Nevertheless, the diminished enzymatic activity of PHEV 
NS2 relative to the other PDEs, suggests that while a PDE may have been 
essential in the PHEV ancestor, it may not be required in the cells targeted by 
PHEV in its porcine host. However, RNase L is likely actively antiviral in other 
porcine tissues or stages of development, as suggested by the presence of an 
RNase L antagonist in protein 7 of transmissible gastroenteritis virus (33). 
 
Although the chimeric MHVs encoding OC43-NS2 and BEV pp1a-CTD do 
not replicate quite as well as MHV in vivo (Fig 2.6), this is unlikely due to 
disruption of the ORF4 gene by insertion of the exogenous PDEs as ablation of 
ORF4 expression within the genome of MHV strain JHM had no effect on 
replication in vitro and in vivo pathogenesis and the MHV strain A59 ORF4 is 
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disrupted by a termination codon (34). Nevertheless, these chimeric viruses 
replicated robustly in vivo causing hepatitis and their respective mutants 
replicated to wild-type titers in the livers of RNase L-/- mice, indicating that 
restriction of the mutants in WT B6 mice is due to RNase L activity. 
 
Overall, we have demonstrated that active 2’,5’ PDEs are a conserved 
feature of lineage A Betacoronavirus genomes, and that a homologous domain is 
encoded in the first open reading frame of a related nidovirus, BEV. This 
suggests that RNase L is a potent antiviral effector in diverse species and 
tissues, due to the wide host range represented by the viruses encoding these 
now-characterized PDEs. This thus far includes the lineage A and lineage C 
betacoronaviruses as well as the related toroviruses and the unrelated group A 
Rotaviruses (6, 9). Finally since 2’,5’ PDEs are potent antagonists of host 
antiviral defenses encoded by multiple and diverse viruses within Coronaviridae, 
this class of protein may have the potential to be a broad-spectrum therapeutic 
target for human viruses including HCoV-OC43, a ubiquitous agent of the 
common cold, and MERS-CoV. 
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Chapter 3 
 
ANTAGONISM OF dsRNA-INDUCED INNATE IMMUNE 
PATHWAYS BY NS4A AND NS4B ACCESSORY 
PROTEINS DURING MERS-COV INFECTION 
 
 
 
 
 
 
This chapter is in production at mBio (as of March 4, 2019) as the published 
article “Antagonism of dsRNA-induced innate immune pathways by NS4a and 
NS4b accessory proteins during MERS-CoV infection by Courtney E. Comar*, 
Stephen A. Goldstein*, Yize Li, Boyd Yount, Ralphs S. Baric, and Susan R. 
Weiss.  
 
*These authors made equivalent contributions  
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Abstract 
Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in 
2012 as a novel etiological agent of severe respiratory disease in humans. As 
during infection by other viruses, host sensing of viral dsRNA induces several 
antiviral pathways. These include interferon (IFN), OAS-RNase L, and Protein 
Kinase R (PKR). Coronaviruses, including MERS-CoV, potently suppress the 
activation of these pathways, inducing only modest host responses. Our study 
describes the functions of two accessory proteins unique to MERS-CoV and 
related viruses, NS4a and NS4b, during infection in human airway epithelium-
derived A549 cells. NS4a has been previously characterized as a double 
stranded RNA (dsRNA) binding protein, while NS4b is a 2’,5’ phosphodiesterase 
with structural and enzymatic similarity to the NS2 protein encoded by mouse 
hepatitis virus (MHV). We found that deletion of NS4a results in increased 
interferon lambda (IFNL1) expression, as does mutation of either the catalytic 
site or nuclear localization sequence of NS4b. All of the mutant viruses we tested 
exhibited slight decreases in replication. We previously reported that, like MHV 
NS2, NS4b antagonizes OAS-RNase L, but suppression of IFN is a previously 
unidentified function for viral phosphodiesterases. Unexpectedly, deletion of 
NS4a does not result in robust activation of the PKR or OAS-RNase L pathways. 
Therefore, MERS-CoV likely encodes other proteins that contribute to 
suppression or evasion of these antiviral innate immune pathways that should be 
an important focus of future work. This study provides additional insight into the 
complex interactions between MERS-CoV and the host immune response. 
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Importance 
Middle East respiratory syndrome coronavirus (MERS-CoV) is the second novel 
zoonotic coronavirus to emerge in the 21st century and cause outbreaks of 
severe respiratory disease. More than 2,200 cases and 800 deaths have been 
reported to date, yet there are no licensed vaccines or treatments. Coronaviruses 
encode unique accessory proteins that are not required for replication but most 
likely play roles in immune antagonism and/or pathogenesis. Our study describes 
the functions of MERS-CoV accessory proteins NS4a and NS4b during infection 
of a human airway-derived cell line. Loss of these accessory protein during 
MERS-CoV infection leads to host antiviral activation and modestly attenuates 
replication. In the case of both NS4a and NS4b, we have identified roles during 
infection not previously described, yet the lack of robust activation suggests 
much remains to be learned about the interactions between MERS-CoV and the 
infected host. 
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Introduction 
Middle East respiratory syndrome-associated coronavirus (MERS-CoV), is 
a recently emerged, highly pathogenic coronavirus first identified in the Middle 
East in 2012 (1, 2). Following the 2002-2003 SARS-CoV pandemic, MERS-CoV 
is the second zoonotic coronavirus discovered in the 21st century. Though cases 
have been largely concentrated on the Arabian Peninsula, a large travel-
associated outbreak in South Korea in 2015 highlights that MERS-CoV remains a 
global concern. MERS-CoV circulates in dromedary camels in Africa and the 
Middle East, having established a reservoir in camels, while closely related 
viruses are found in African bats, suggesting a bat origin for MERS-CoV or its 
direct ancestors (3-9). 
 
Like all coronaviruses, MERS-CoV has a large positive-sense single-
stranded RNA (ssRNA) genome of 30,119 nucleotides in length. The 5’ two-
thirds of the genome encode the functionally conserved replicase proteins, while 
a core set of structural proteins are encoded by all viruses of the Betacoronavirus 
genus in the 3’ 10 kb. Additionally found in the 3’ end of the genome are 
accessory genes specific to each Betacoronavirus subgenus, interspersed with 
structural genes. The MERS-CoV accessory genes are found only in other 
betacoronaviruses of the subgenus Merbecovirus (formerly lineage C) while 
betacoronaviruses of other subgenera such as mouse hepatitis virus (MHV) 
(Embecovirus/lineage A) and SARS-CoV (Sarbecovirus/lineage B) encode 
unique accessory genes. 
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Several accessory proteins encoded by MHV and SARS-CoV have been 
identified as antagonists of the innate immune response (10), as have some 
MERS-CoV accessory proteins (11-16). Several studies utilizing ectopically 
expressed protein and reporter systems have identified NS4a, NS4b, and NS5 as 
putative interferon (IFN) antagonists, but these studies may not faithfully 
recapitulate the complex interactions between viral and host factors present 
during infection (12, 13, 15, 17, 18). Recent studies utilizing recombinant MERS-
CoV have more completely elucidated the functions of some of these proteins, 
but in some cases conflict with the earliest studies. NS4a, a double-stranded 
RNA (dsRNA) binding protein, prevents the generation of PKR-induced stress 
granules in some cell types (19). We reported previously that NS4b is a homolog 
of the NS2 protein of MHV and closely related betacoronaviruses of the 
subgenus Embecovirus (formerly lineage A), has 2’,5’ phosphodiesterases (PDE) 
activity, and acts as an antagonist of the oligoadenylate synthetase-ribonuclease 
L (OAS-RNase L) pathway (20). In contrast to the Embecovirus PDEs, NS4b has 
an N-terminal nuclear localization signal (NLS) and is localized primarily to the 
nucleus of infected cells (17, 20). NS4b has also been reported to antagonize 
NFκB nuclear translocation during MERS-CoV (14, 16, 19, 20), as has NS5 (11). 
 
Building on our previous study characterizing NS4b as an OAS-RNase L 
antagonist (20), we have used recombinant MERS-CoV to further elucidate the 
roles of NS4a and NS4b during infection of human airway epithelium-derived 
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A549 cells (21). Consistent with earlier studies, NS4a prevents phosphorylation 
of PKR and the induction of IFN and interferon-stimulated gene (ISG) expression. 
However, PKR activation in the absence of NS4a does not result in 
phosphorylation of eIF2α or translation arrest in A549 cells, in contrast to recent 
findings in a different cell type (19). Unlike other viral dsRNA binding proteins 
such as Vaccinia virus E3L (22) and influenza virus NS1 (23), NS4a does not 
play a significant role in OAS-RNase L antagonism during MERS-CoV infection, 
as deletion of NS4a does not result in RNase L activation or enhance RNase L 
activation in the context of MERS-CoV encoding catalytically inactive NS4b. 
 
Our studies of NS4b reveal that in addition to antagonizing OAS-RNase L 
and preventing NFκB activation, NS4b antagonizes IFNL1 expression, with this 
function dependent on both its catalytic activity and nuclear localization and 
independent of its interaction with the OAS-RNase L pathway. This is a unique 
role for virus-encoded phosphodiesterases, which otherwise lack an NLS and act 
solely as OAS-RNase L antagonists (14, 24-27). Together, the results 
demonstrate that NS4a and NS4b mediate both expected and unexpected 
functions during MERS-CoV infection, and further demonstrate the importance of 
studying the function of these proteins in the context of infection to uncover the 
full range of their interactions with the innate immune response. 
 
 
 
 78 
Materials and Methods 
 
Recombinant viruses. Recombinant WT MERS-CoV and mutants were derived 
from the EMC/2012 strain cDNA clone all by introducing mutations into cDNA 
fragment F assembling the genome fragment and recovering infectious virus as 
described previously (28). 
 
To ablate expression of MERS NS4a, PCR was performed with primers 
EMCmut4A (5’-
NNNNNNTTAATTAACGAACTCTATTGATTACGTGTCTCTGCTTAATCAAATTT
GACAGAAGTACCTTAACTC-3') and MERS:F3941 (5’-
CACCGAAATGCATGCCAGCC-3'). The position of the F3941 within the MERS 
genome is 28,321 to 28,302. This product was digested with PacI and NcoI, gel 
purified, and then ligated into the MERS F plasmid which had been similarly 
digested. 
 
To ablate MERS NS4a and NS4b expression, PCR was performed with 
primers delta4AB (5’-NNNNNNTTAATTAAGTTCATTCTTATCCCATTTTACATC-
3’) and MERS:F3415 (5’-GAGGGGGTTTACTATCCTGG-3’).  This product was 
digested with PacI and SanDI, gel purified and then ligated into the MERS F 
plasmid which had been similarly digested. The delta4AB primer uses the PacI 
site just upstream of NS4a, then the rest of this primer’s sequence is from 26,795 
to 26,819 in the MERS genome. The deletion removes nucleotides 25,844 to 
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26,794 in the MERS genome, and does not disrupt either the ~40 nucleotides 
upstream of or the transcription regulatory sequence (TRS) of NS5. 
 
MERS-NS4bH182R was previously described (20). MERS-4bNLSmut was 
constructed by substituting residues 31, 33, 36, 37, 38 and 43 each with 
alanine.  Briefly, one PCR product was generated using primers 
MERS:F1376 (5’-GTTTCTGTCGATCTTGAGTC-3’) and MERS4bR (5’-
NNNNNNCGTCTCGCAACGTAGGCCAGTGCCTTAGTTGGAGAATGGCTCCTC
-3’).  A second PCR reaction was performed with the primers MERS4bF (5’-
NNNNNNCGTCTCCGTTGCGGCTGCATTTTCTCTTCTGGCCCATGAAGACCT
TAGTGTTATTG-3’) and MERS:F3415 (5’-GAGGGGGTTTACTATCCTGG-
3’). The position of the F1376 primer in context of the MERS genome is 25,748-
25,767, while the position for the reverse F3415 primer is 27,815-27,796. The 
products were gel isolated, digested with BsmBI (underlined in the above 
primers) and ligated with T4 DNA ligase.  The resultant product was digested 
with PacI and SanDI, gel purified, and then used to replace the corresponding 
region in the MERS F plasmid which had been similarly digested.   All 
recombinant viruses were isolated as previously described (28). 
 
Sindbis virus Girdwood (GW100) (SINV) was obtained from Dr. Mark 
Heise, University of North Carolina, Chapel Hill, and prepared as previously 
described (29) and Sendai virus (SeV), Cantell strain was obtained from Dr. 
Carolina Lopez, University of Pennsylvania, Philadelphia and prepared as 
 80 
previously described (30). 
 
Cell lines. Vero CCL-81 cells were cultured in DMEM+10% FBS, penicillin-
streptomycin, gentamicin, sodium pyruvate, and HEPES. Human A549 cells were 
cultured in RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin. 
A549DPP4 and 293TDPP4 cells were constructed by lentivirus transduction of 
DPP4. The plasmid encoding the cDNA of DPP4 was purchased from Sino 
Biological. The cDNA was amplified using forward primer: 
5’-GACTCTAGAATGAAGACACCGTGGAAGGTTCTTC-3’ and reverse primer: 
5’-
TCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAGGTAAAGAGAAACAT
TGTTTTATG-3’. A V5 tag was introduced to the 3’ end of the cDNA by PCR to 
enable easy detection of DPP4. The amplicon was cloned into pCR4-TOPO TA 
cloning vector (Invitrogen #K457502), to make pCR4-DDP4-V5. The fragment 
containing DPP4-V5 was digested by XbaI/SalI restriction enzymes from the 
pCR4-DPP4-V5 and was cloned into pLenti-GFP in place of GFP, generating 
pLenti-DPP4-V5. The resulting plasmids were packaged in lentiviruses 
pseudotyped with VSV-G to establish the gene knock in cells as previously 
described (31). Forty-eight hours after transduction cells were subjected to 
hygromycin (1mg/ml) selection for 3 days and single-cell cloned. Clones were 
screened for DPP4 expression and susceptibility to MERS-CoV replication. 
RNase L knockout A549DPP4 cells were generated as previously described for 
parental A549 (31) cells.  A549mCEACAM-1 cells were generated as described 
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above for A549DPP4 cells, but by insertion of mouse Ceacam-1 (Genbank 
accession #: NM_001039185.1) into the lentivirus vector rather than human 
DPP4. 
 
NS4b expression from pCAGGs plasmid. WT NS4b and the indicated mutant 
NS4b constructs were synthesized and purchased from Bio Basic in vector 
pUC57 flanked by restriction sites ClaI/XhoI. pUC57 plasmids were digested and 
NS4b fragments gel purified for ligation into pCAGGS expression vector. Ectopic 
expression was conducted using lipofectamine 2000 transfection reagent 
(Thermo Fisher # 11668027) following the provided protocol. 24 hours post-
transfection cells were fixed and stained as described below. 
 
MERS-CoV infections and titration. Viruses were diluted in serum-free RPMI 
and added to cells for absorption for 45 minutes at 37°C. Cells were washed 
three times with PBS and fed with RPMI+2% FBS. 150 µl of supernatant was 
collected at the times indicated and stored at -80°C for titration by plaque assay 
on Vero CCL-81 cells as previously described (28). All infections and virus 
manipulations were conducted in a biosafety level 3 (BSL3) laboratory using 
appropriate personal protective equipment and protocols. 
 
Immunofluorescent staining. At indicated times post-infection cells were fixed 
with 4% paraformaldehyde for 30 minutes at room temperature. Cells were then 
washed three times with PBS and permeabilized for 10 minutes with PBS+0.1% 
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Triton-X100. Cells were then blocked in PBS and 2% BSA for 45-60 minutes at 
room temperature. Primary antibodies were diluted in block buffer and incubated 
on a rocker at room temperature for one hour. Cells were washed three times 
with block buffer and then incubated rocking at room temperature for 30 minutes 
with secondary antibodies diluted in block buffer. Finally, cells were washed twice 
with block buffer and once with PBS, and nuclei stained with DAPI diluted in 
PBS. Coverslips were mounted onto slides for analysis by confocal microscopy. 
NS4b was detected using anti-NS4b rabbit serum at 1:500 and NS4a with anti-
NS4a rabbit serum at 1:500 (both obtained from Dr. Luis Enjuanes, Spanish 
National Centre for Biotechnology) (14). DsRNA was detected using commercial 
antibody J2 at 1:1000 and nsp8 using anti-nsp8 guinea pig serum (obtained from 
Dr. Mark Denison, Vanderbilt University). Secondary antibodies were all highly 
cross-adsorbed IgG (H+L) from Invitrogen: Goat-anti rabbit AF594 (Cat #: 
AA11037), goat anti-mouse AF488 (Cat #: AA11029), goat anti-rabbit AF647 
(Cat #: A32733), goat anti-guinea pig AF594 (Cat #: A11076), goat anti-guinea 
pig AF568 (Cat #: A11075). 
 
Western immunoblotting. Cells were washed twice with ice-cold PBS and 
lysates harvested at indicated times post infection with lysis buffer (1% NP40, 
2mM EDTA, 10% glycerol, 150mM NaCl, 50mM Tris HCl) supplemented with 
protease inhibitors (Roche – cOmplete mini EDTA-free protease inhibitor) and 
phosphatase inhibitors (Roche – PhosStop easy pack). After 5 minutes lysates 
were harvested, incubated on ice for 20 minutes, centrifuged for 20 minutes at 
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4°C and supernatants mixed 3:1 with 4x Laemmli sample buffer. Samples were 
heated at 95°C for 5 minutes, then separated on 4-15% SDS-PAGE, and 
transferred to polyvinylidene difluoride (PVDF) membranes. Blots were blocked 
with 5% nonfat milk and probed with the following antibodies diluted in the same 
block buffer: anti-PKR (phospho-T446) [E120] rabbit mAb at 1:1000 (Abcam 
32036), anti-PKR (D7F7) rabbit mAb at 1:1000 (Cell Signaling Technology 
12297), anti-GAPDH (14C10) rabbit mAb (Cell Signaling Technology 2118) at 
1:1000, SinoBiological anti-MERS N mouse mAb at 1:1000, anti-NS4a rabbit 
serum at 1:500 (obtained from Dr. Luis Enjuanes, Spanish National Centre for 
Biotechnology) (14), and anti-NS4b rabbit serum at 1:500 (obtained from Dr. 
Robert Silverman, Cleveland Clinic) {Canton, 2018 #4007}. For detection of 
eIF2α and phosphorylated eIF2α, blots were blocked with 5% BSA and probed 
with the following antibodies diluted in the block buffer: phospho-eIF2α (Ser51) 
antibody at 1:1000 (Cell Signaling Technology 9721). Secondary antibodies used 
were: Santa Cruz goat anti-mouse IgG-HRP secondary antibody (SC2005) at 
1:5000 and Cell Signaling Technology anti-rabbit IgG, HRP-linked secondary 
antibody (CS7074) at 1:3000. Blots were visualized using Thermo Scientific 
SuperSignal west chemiluminescent substrates (Cat #: 34095 or 34080). Blots 
were probed sequentially with antibodies and in between antibody treatments 
stripped using Thermo scientific Restore western blot stripping buffer (Cat #: 
21059). 
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Protein synthesis was assessed by treatment of cells with 10µg/ml puromycin for 
10 minutes prior to protein harvest (32). Lysates were harvested and run on 
SDS-PAGE gels as described above. For detection of puromycin, anti-puromycin 
mouse mAb (Millipore clone 4G11 MABE342) was used at 1:6000, and the 
secondary antibody used was goat anti-mouse IgG-HRP Thermo Scientific 
(31430) at 1:3000. For detection of total protein by Coomassie staining, cell 
lysates (as prepared above) were separated by 4-15% SDS-PAGE. Gels were 
fixed and stained with 0.05% Coomassie Brilliant Blue R250 (Biorad 161-0400) in 
50% methanol, 10% acetic acid solution for 2 hours at a gentle rock at room 
temperature. Gels were de-stained with 7% methanol and 5% acetic acid for 
several hours and then imaged. 
 
Quantitative real time PCR (qRT-PCR). At indicated times post-infection cells 
were lysed with buffer RLT Plus (Qiagen RNeasy Plus #74136) and RNA 
extracted following the prescribed protocol. cDNA was synthesized according to 
the protocol for Thermo Scientific Superscript III reverse transcriptase (Thermo 
Scientific #18080044). RT-qPCR was performed under conditions validated for 
the indicated primer set. Primer sequences are as follows: IFNL1 (F: 5’- 
CGCCTTGGAAGAGTCACTCA-3’ R: 5’- GAAGCCTCAGGTCCCAATTC-3’), 
OAS2 (F: 5’- TTCTGCCTGCACCACTCTTCACGAC-3’ R: 5’- 
GCCAGTCTTCAGAGCTGTGCCTTTG-3’), IFIT2 (F: 5’- 
CTGAGAATTGCACTGCAACCATG-3’ R: 5’- 
TCCCTCCATCAAGTTCCAGGTGAA-3’), IFNB (F: 5’- 
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GTCAGAGTGGAAATCCTAAG-3’ R: 5’-ACAGCATCTGCTGGTTGAAG-3’), 
GAPDH (F: 5’-GCAAATTCCATGGCACCGT-3’ R: 5’-
TCGCCCCACTTGATTTTGG 
-3’). Fold changes in mRNA were calculated using the formula 2-∆(∆Ct)(ΔCt = 
Ctgene of interest – CtGAPDH) and expressed as fold infected/mock-infected. 
 
Analyses of RNase L-mediated rRNA degradation. RNA was harvested with 
buffer RLT (Qiagen RNeasy #74106) and analyzed on an RNA chip with an 
Agilent Bioanalyzer using the Agilent RNA 6000 Nano Kit and its prescribed 
protocol as we have described previously (Cat #: 5067-1511). 
 
Statistical analysis. Plotting of data and statistical analysis were performed 
using GraphPad Prism software (GraphPad Software, Inc., CA). Statistical 
significance for viral replication curves was determined by two-way ANOVA and 
for RT-qPCR by unpaired student’s t-test. 
 
Results 
 
Construction and characterization of recombinant NS4a and NS4b MERS-
CoV mutants. In order to study the effects of NS4a and NS4b on MERS-CoV 
interactions with the host innate immune system we used a panel of recombinant 
MERS-CoV mutants. Deletion mutants MERS-ΔNS4a, MERS-ΔNS4ab were 
generated from the MERS-CoV infectious clone derived from the MERS-
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EMC2012 strain (28) as follows and are described in detail in Materials and 
Methods and diagramed in Figure 3.1A-B. Briefly, MERS-ΔNS4a was generated 
by altering the start codon 
(ATGàATT) and adding an in-frame 
stop codon ten codons downstream 
(TGGàTGA) to ablate synthesis of 
the NS4a protein. MERS-ΔNS4ab 
was generated by engineering a 951 
nucleotide deletion of ORF4a and the 
majority of ORF4b without disrupting 
the transcription regulatory sequence 
(TRS) of NS5.  To verify the loss of 
NS4b and/or NS4a expression by 
these mutants, human A549 cells 
stably expressing the MERS-CoV 
receptor DPP4 (A549DPP4) were 
infected with MERS-CoV mutants at 
an MOI of 10 and protein lysates 
harvested at 24 and 48 hours post-
infection to assess protein expression by western blot. As expected, NS4a is not 
synthesized during infection with MERS-ΔNS4a, and neither protein is detectable 
during MERS-ΔNS4ab infection (Fig 3.1C). 
 
Figure 3.1. MERS-CoV NS4a and NS4b 
recombinant mutants. (A) MERS-CoV genome RNA 
with open reading frames shown. (B) NS4a and NS4b 
proteins expressed by wild type and mutant MERS-
CoVs.  The catalytic His residues of the PDE are 
shown and the vertical black bar indicates the NLS of 
NS4b; the red lettering indicates amino acid 
substitutions of the catalytic His residue and within the 
NLS (C) Expression of viral proteins from recombinant 
MERS-CoV viruses. A549DPP4 cells were infected at an 
MOI of 10 with WT MERS-CoV, MERS-NS4a, MERS-
NS4ab, MERS-NS4bH182R, MERS-NS4bNLSmut or mock 
infected. Cell lysates were prepared at 24 and 48 hours 
post-infection, analyzed by SDS-PAGE and probed by 
western blot with rabbit anti-serum against NS4a and 
NS4b, or mouse monoclonal antibodies against MERS 
nucleocapsid protein (N) and GAPDH. Contributors: 
SAG and CEC 
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To further investigate the functional domains of NS4b, we utilized two 
mutant viruses with targeted mutations in either the phosphodiesterase domain 
or the NLS. MERS-NS4bH182R encodes NS4b with a catalytically inactive 
phosphodiesterase domain, which was generated from the MERS-CoV infectious 
clone as previously described (20, 28).  
 
The NS4b NLS was previously described as bipartite (RKR11KRR), with 
the first basic motif more potently determining nuclear localization (14, 17). 
However, this first motif overlaps with the upstream ORF4a and so mutation of 
the RKR motif without causing amino acid changes in ORF4a is impossible. To 
determine how to construct NS4bNLSmut we mapped the nuclear localization 
sequence (NLS) by expressing WT and various NLS-mutant NS4b genes from a 
pCAGGS vector in A549 cells and detecting NS4b proteins by 
immunofluorescent staining (Fig 3.2A). These plasmids expressed NS4b proteins 
with mutations of the RKR motif, the downstream KRR motif, and a previously 
undescribed basic motif that lies between the two previously characterized motifs 
(RKR5KKLR2KRR). All mutant proteins exhibited primarily cytoplasmic 
localization, thus we engineered mutation of the central (KKLR) and downstream 
(KRR) motifs into the MERS-CoV infectious clone to generate MERS-NS4bNLSmut 
(Fig 3.1B), as described in detail in Materials and Methods (28). 
 
While NS4b expressed during MERS-CoV infection is primarily expressed 
in the nucleus, during infection with MERS-NS4bNLSmut, NS4b exhibits 
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predominantly cytoplasmic localization, as expected (Fig 3.2B).  During infection 
with MERS-NS4bH182R and MERS-NS4bNLSmut, slightly less NS4b was 
synthesized than during wild-type 
(WT) MERS-CoV infection (Fig 3.1C), 
consistent with previous studies of 
viral PDEs in which mutant protein 
expression was less robust than 
expression of wild-type protein (20). 
We consistently detected an extra 
lower band when probing for NS4b. 
This will be addressed in the 
Discussion. 
 
NS4a colocalizes with dsRNA 
around replication/transcription 
complexes (RTC). Previous studies 
have shown that overexpressed NS4a binds to dsRNA (15, 18). Additionally, 
NS4a is broadly cytoplasmic when overexpressed in uninfected cells, but co-
localizes with dsRNA during infection (12, 14, 15). We infected A549DPP4 cells 
with MERS-CoV and used immunofluorescent microscopy to determine NS4a 
localization. NS4a exhibits primarily punctate, perinuclear distribution with some 
diffuse distribution in the cytoplasm (Fig 3.3). Cells were co-stained for NS4a with 
J2 antibody to detect dsRNA and antiserum against the viral primase, nsp8, a 
Figure 3.2. Subcellular localization of MERS-CoV 
NS4b expression. (A) The nuclear localization 
signal (NLS) was mapped by mutating basic 
residues in pCAGGS-NS4b and NS4b was 
ectopically expressed in A549 cells by DNA 
transfection. Twenty four hours post-transfection cells 
were fixed and stained for NS4b using anti-NS4b 
rabbit serum. (B)  A549DPP4 cells were infected with 
WT MERS-CoV, MERS-NS4bH182R, or MERS-
NS4bNLSmut (MOI=5). Cells were fixed 24 hours post-
infection and stained with anti-NS4b rabbit serum 
and goat anti-rabbit AF594 secondary antibody. 
Contributor: SAG 
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component of the viral polymerase complex and therefore a marker for virus 
RTCs (33). NS4a co-localizes with dsRNA and both are largely co-localized with 
nsp8, though dsRNA/NS4a appear more broadly distributed (Fig 3.3). This may 
indicate either that some 
dsRNA and NS4a localized 
outside the RTC, or that 
sensitivity of the assay is 
insufficient to detect all of 
the nsp8.  
 
NS4a and NS4b deletion mutants are modestly attenuated in A549
DPP4
 cells. 
To assess the impact of NS4a and NS4b mutation on viral replication, we carried 
out growth curves in Vero and A549DPP4 cells with MERS-∆NS4a and MERS-
∆NS4ab. Vero cells lack a type I IFN response and were used to ensure 
recombinant viruses are not inherently replication-deficient. We infected both cell 
types with WT or mutant MERS-CoV at MOI=1 and harvested supernatant at pre-
determined times post-infection for titration by plaque assay. All viruses 
replicated with equivalent kinetics to WT MERS-CoV and to equal titers in Vero 
cells, indicating that deletion of NS4a and NS4b does not disrupt critical aspects 
of the viral life-cycle (Fig 3.4A). In contrast, deletion of NS4a and/or NS4b 
modestly attenuated MERS-CoV replication in A549DPP4 cells at an MOI of 1, with 
the reductions in titer significant at most time points (Fig 3.4B-C). Deletion of both 
NS4a and NS4b resulted in a slightly greater attenuation than deletion of NS4a 
Figure 3.3. NS4a colocalizes with dsRNA around 
replication/transcription complexes (RTC) during MERS-CoV 
infection. A549DPP4 cells were infected with WT MERS-CoV (MOI=5), 
fixed 24 hours post-infection, and stained with rabbit anti-NS4a 
serum, mouse anti-dsRNA J2, and guinea pig anti-nsp8 serum and 
then with secondary antibodies goat anti-rabbit AF647, goat anti-
mouse AF488, and goat anti-guinea pig AF568. Contributor: SAG 
and CEC 
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alone, though this difference was not statistically significant.  That replication of 
these mutant viruses is attenuated in A549DPP4 cells and not in permissive Vero 
cells strongly suggests that the deficiency is linked to the intact antiviral 
responses in A549 cells.  
 
NS4a and NS4b modestly suppress 
IFN expression. Previous studies of 
NS4a and NS4b have conflicted on the 
role of these proteins in suppressing the 
IFN response (12-16, 19). We aimed to 
systematically characterize the role of 
NS4a and NS4b in antagonism of 
IFN induction during MERS-CoV 
infection. To ensure that our 
newly generated A549DPP4 cells 
were a suitable platform for 
investigating MERS-CoV 
suppression of the IFN response, we infected them with Sendai virus (SeV), 
Sindbis virus (SINV), and WT MERS-CoV. In contrast to SeV and SINV, which 
robustly induced IFN and ISG expression by 12 hpi, MERS-CoV induced little 
IFNL1 or IFNB expression throughout a 36-hour course of infection (3.5A-B). 
 
Figure 3.4. MERS-CoV NS4a and NS4b mutants are 
attenuated in IFN-competent cells. (A) Vero cells were 
infected in triplicate at MOI=1 with WT MERS-CoV, MERS-
NS4a, and MERS-NS4ab. Supernatants were collected at 
indicated times post-infection and infectious virus quantified 
by plaque assay. (B) A549DPP4 cells were infected in triplicate 
at MOI=1 with WT MERS-CoV, MERS-NS4a, and MERS-
NS4ab and replication quantified as in (A). (C) Statistical 
significance for mutant virus replication vs WT was 
calculated by two-way ANOVA. Data are from one 
representative of three independent experiments. In (A) the 
72 hours post-infection data point was only assessed in one 
out of three experiments. Data are displayed as means ± 
standard deviation (SD); * p ≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, 
**** p≤ 0.0001. Contributors: CEC and SAG 
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 To determine if NS4a and/or NS4b contribute to suppressing IFN 
expression, we infected A549DPP4 cells with WT MERS-CoV, MERS-∆NS4a, and 
MERS-∆NS4ab and at 24 and 36 hours post-infection compared gene 
expression of IFN and selected ISGs by qRT-PCR. In contrast to the minimal 
increases observed during WT MERS-CoV infection over mock-infected cells, 
MERS-∆NS4a or 
MERS-∆NS4ab infection 
resulted in significantly 
elevated levels of IFNL1 
mRNA and 
representative ISGs 
OAS2 and IFIT2 
mRNAs. Interestingly 
there was no significant 
induction of type I IFN 
(Fig 3.5C). We did not 
observe any significant 
additive effect on 
antiviral gene 
expression from the 
additional deletion of NS4b. However, deletion of ORFs 4a and/or 4b did not 
result in IFN induced approaching the levels we observed in response to SeV 
and SINV infection (Fig 3.5B), suggesting MERS-CoV encodes additional, potent 
Figure 3.5. NS4a and NS4b antagonize IFN expression. (A) A549DPP4 
cells were mock-infected or infected in triplicate with WT MERS-CoV at 
MOI=5.  RNA was harvested and gene expression was quantified by 
qRT-PCR and expressed as fold over mock-infected using the 2-Δ(ΔCt) 
formula. (B) A549DPP4 cells were infected in triplicate with SeV or SINV at 
MOI=5 and at 12 hours post-infection expression of the indicated genes 
in infected/mock-infected cells calculated as in (A). (C) A549DPP4 cells 
were mock-infected or infected in triplicate with WT MERS-CoV, MERS-
NS4a, and MERS-NS4ab at MOI=5 and RNA harvested at the indicated 
times post-infection. IFNL1, IFNB, OAS2, and IFIT2 mRNA levels were 
quantified by qRT-PCR and calculated over mock-infected cells 
calculated as in (A). Data are from one representative of three 
independent experiments and displayed as means ± standard errors of 
the mean (SEM). Statistical significance was calculated by unpaired 
student’s t-test; * p ≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. 
Contributor: SAG 
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IFN antagonists and/or utilizes other mechanisms such as sequestration of 
dsRNA in membrane-bound RTCs to  
evade sensing by antiviral receptors. 
 
NS4b is a novel IFN antagonist. We 
previously reported that MERS-CoV 
NS4b is a member of the 2H-
phosphoesterase superfamily of 
proteins and antagonizes OAS-
RNase L activation during MERS-
CoV infection through its 2’,5’ PDE 
activity (20, 34). 
Unlike previously 
studied viral 
PDEs such as 
mouse hepatitis 
virus (MHV) NS2, 
the torovirus 
pp1a C-terminal 
domain and the rotavirus VP3 C-terminal domain which exhibit primarily 
cytoplasmic localization (24, 25), NS4b localizes primarily to the nucleus (Fig 
3.2B), suggesting additional functions. Earlier studies suggested that NS4b 
nuclear localization might be important for suppressing IFN expression (13), but 
Figure 3.6. MERS-CoV NS4b NLS and PDE catalytic mutants are attenuated in 
A549 cells and exhibit increased type III IFN expression. (A) Vero cells were 
infected in triplicate at MOI=1 with WT MERS-CoV, MERS-NS4a, and MERS-
NS4ab. Supernatants were collected at indicated times post-infection and infectious 
virus quantified by plaque assay. (B) A549DPP4 cells were infected in triplicate at 
MOI=1 or 0.1 with WT MERS-CoV, MERS-NS4a, and MERS-NS4ab and replication 
quantified as in (A). Data are from one representative of three independent 
experiments and displayed as means ± standard deviation (SD). (C) Statistical 
significance for mutant virus replication vs WT was determined by two-way ANOVA; 
* p ≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. (D) A549DPP4 cells were mock 
infected or infected in triplicate at MOI=5 with WT MERS-CoV, MERS-NS4bNLS, and 
MERS-NS4bH182R and RNA harvested at the indicated times post-infection. Gene 
expression over mock-infected cells was measured by RT-qPCR and calculated 
over mock-infected cells using the 2-Δ(ΔCT) formula. Data are from one representative 
of three independent experiments and expressed as mean ± SEM. Statistical 
significance was determined by unpaired student’s t-test;  * p ≤ 0.05, ** p≤ 0.01, *** 
p≤ 0.001, **** p≤ 0.0001. (E) A549mCEACAM-1 cells were mock treated or infected with 
WT MHV or MHV-NS2H126R at MOI=5 and RNA harvested at 6 and 12 hours post-
infection. IFNL1 expression was determined as in (D). Data are from one 
representative experiment of three. Contributor: SAG 
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no previous studies have specifically addressed the role of its catalytic activity in 
IFN antagonism (35).  
 
To characterize the function of the NS4b PDE domain and NLS we used 
recombinant MERS-NS4bH182R and MERS-NS4bNLSmut. In Vero cells both mutant 
viruses replicated with equivalent 
kinetics to WT MERS-CoV and to 
equal titers (Fig 3.6A). In A549DPP4 
cells both viruses are modestly 
and similarly attenuated at late 
time points at an MOI of 1, and 
throughout the course of infection 
at an MOI of 0.1, where two out of 
three independent experiments 
yielded significant differences (Fig 
3.6B-C).   qRT-PCR analysis 
demonstrated that mutation of 
either the catalytic site or NLS 
results in significantly increased 
IFN and ISG expression during 
MERS-CoV infection (Fig 3.6D).  
 
Figure 3.7. NS4b antagonizes IFN expression 
independently of RNase L activation. (A) RNase L KO 
A549DPP4 cells were mock infected or infected in triplicate 
at MOI=5 with MERS-CoV, MERS-NS4bNLS, and MERS-
NS4bH182R. RNA was harvested at the indicated times 
post-infection, mRNA levels expression was quantified by 
qRT-PCR in and expression in infected/mock-infected 
cells calculated using the 2-Δ(ΔCt) formula. Data are from 
one representative experiment of three, expressed as 
mean ± SEM and statistical significance determined by 
unpaired student’s t-test; p ≤ 0.05, ** p≤ 0.01, *** 
p≤ 0.001, **** p≤ 0.0001. (B) A549DPP4 and RNase L KO 
A549DPP4 cells were mock treated or infected with SINV at 
MOI=1with SINV and RNA was harvested at 24 hours 
post-infection. RNA was assessed for ribosomal RNA 
degradation using an Agilent Bioanalyzer. 28S and 18S 
rRNA positions are indicated. Contributor: SAG 
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To further investigate whether PDE-dependent IFN antagonism is unique 
to MERS-CoV NS4b, we infected A549 cells stably expressing the MHV receptor 
CEACAM-1 (A549mCEACAM-1) with WT MHV or MHV encoding catalytically inactive 
NS2 (MHV-NS2H126R), its native PDE. Both viruses induced slightly more IFNL1 
expression than we observed for MERS-CoV, but MHV-NS2H126R did so to an 
identical degree as WT MHV (Fig 3.6E) demonstrating that the MHV PDE does 
not antagonize IFN induction in this cell type, consistent with our previous 
observation in murine cells (36).  
 
Finally, to confirm that NS4b antagonism of IFN expression is a novel viral 
PDE function and uncoupled from its interaction with the OAS-RNase L pathway 
we assessed immune activation by MERS-CoV and NS4b mutants in A549DPP4 
cells ablated of RNase L expression by CRISPR-Cas9 as previously described 
(31). Both MERS-NS4bH182R and MERS-NS4bNLSmut induced greater IFNL1, 
OAS2, and IFIT2 expression than WT MERS-CoV (Fig 3.7A) in RNase L KO 
cells, recapitulating the results we observed in wild-type A549DPP4 cells. To 
confirm that these cells were indeed unable to activate RNase L, cells were 
infected with SINV, a known potent activator of OAS-RNase L (31), and rRNA 
integrity was analyzed by Bioanalyzer as previously described (20, 24).   
 
NS4a does not contribute to OAS-RNase L antagonism during MERS-CoV 
infection. DsRNA binding proteins encoded by viruses such as Vaccinia virus 
(E3L) and Influenza A virus (NS1) antagonize activation of the antiviral OAS-
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RNase L pathway, presumably by sequestration of viral RNA (22, 23, 37). Since 
RNase L activation by MERS-NS4bH182R is less robust than by other viruses such 
as SINV in A549DPP4 cells (Fig 3.7) we hypothesized that NS4a may contribute to 
antagonism of this pathway 
during MERS-CoV infection. To 
test this hypothesis, we infected 
A549DPP4 cells at an MOI of 5 and 
harvested RNA 48 hours-post 
infection and assessed rRNA 
degradation using a Bioanalyzer 
(20, 24). We included SINV as a 
control for robust RNase L 
activation (31). RNase L 
activation is inferred from RNA 
degradation depicted by the 
banding pattern in the pseudogel 
image. MERS-NS4bH182R and MERS-ΔNS4ab induced more rRNA degradation 
than WT MERS-CoV indicating activation of RNase L (Fig 4.8). Infection with 
MERS-NS4bNLSmut also did not result in increased rRNA degradation, as 
expected given previous work demonstrating cytoplasmic PDE localization 
mediates RNase L antagonism (38). However, infection with MERS-ΔNS4a also 
did not induce increased rRNA degradation relative to WT MERS-CoV indicating 
that the absence of NS4a alone is not enough to activate RNase L in this cell 
Figure 3.8. Loss of NS4a does not activate RNase L 
during MERS-CoV infection. A549DPP4 cells were mock 
infected or infected with WT MERS-CoV, MERS-NS4a, 
MERS-NS4ab, MERS-NS4bH182R, MERS-NS4bNLSmut 
(MOI=5) or SINV (MOI = 1). RNA was harvested at 48 hours 
post-infection for MERS-CoV infection and at 24 hours post-
infection for SINV infection and assessed for ribosomal RNA 
degradation by Agilent Bioanalyzer. 28S and 18S rRNA 
positions are indicated. RINs and 28S/18S rRNA ratios are 
shown for each sample. Data are from one representative of 
three independent experiments. Contributor: CEC 
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type (Fig 3.8). Infection with MERS-ΔNS4ab did not induce more robust rRNA 
degradation than MERS-NS4bH182R, suggesting that NS4a does not play a 
significant role in antagonism of RNase L during MERS-CoV infection. This result 
demonstrates that NS4a has both functional similarities and differences to other 
viral dsRNA binding proteins. 
 
NS4a antagonizes PKR 
activation, but not protein 
synthesis, during MERS-CoV 
infection. A recent study showed 
that loss of NS4a during infection 
led to PKR activation, translational 
arrest, and stress granule 
formation, but only in certain cell 
types (19). We investigated 
whether NS4a antagonizes the 
dsRNA binding antiviral effector 
Protein Kinase R 
(PKR) during 
MERS-CoV 
infection in 
A549DPP4 cells. 
A549DPP4 cells 
Figure 3.9. Loss of NS4a activates PKR but does not lead to eIF2α 
phosphorylation or translation arrest in A549
DPP4
. A549DPP4 cells were mock 
infected or infected with WT MERS-CoV and MERS-NS4a (MOI=3) or SINV 
(MOI=1). (A) Cell lysates were harvested at 24 hours-post infection and proteins 
separated by SDS-PAGE and immunoblotted with antibodies against 
phosphorylated PKR (p-PKR), PKR, phosphorylated eIF2α (p-eIF2α), eIF2α, 
MERS-CoV N, and GAPDH. (B) Prior to cell lysate harvest, at 18 and 24 hours 
post-infection cell were treated with puromycin (10μg/ml) for 10 minutes. Proteins 
were separated by SDS-PAGE and analyzed either by immunoblotting with 
antibodies against puromycin, MERS N, or GAPDH or Coomasssie stain for 
labeling of total proteins. (C) 293TDPP4 cells were infected and cell lysates 
harvested same as in (A). (D) 293TDPP4 cells were infected and cell lysates 
harvested as in (B). Data are from one representative of four (A), three (B), or two 
(C,D) independent experiments. Contributor: CEC 
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were infected with WT MERS-CoV and MERS-ΔNS4a at an MOI of 3, lysed at 24 
hours post-infection and analyzed for PKR activation by western blot. MERS-
ΔNS4a, but not WT MERS-CoV induced PKR phosphorylation (Fig 3.9A). PKR 
phosphorylation during MERS-ΔNS4a infection was also observed at 16 and 48 
hours post-infection (data not shown). However, despite the activation of PKR, 
we did not detect phosphorylation of eIF2α above background levels, suggesting 
that activation of PKR by MERS-ΔNS4a in A549DPP4 cells is not sufficient to 
engage downstream elements of this pathway or that MERS-CoV encodes an 
additional antagonist that blocks steps downstream of PKR phosphorylation. In 
contrast, SINV infection promotes robust phosphorylation of PKR and eIF2α in 
the same cells, indicating the lack of eIF2α phosphorylation during MERS-ΔNS4a 
is not due to a deficiency of this pathway in A549DPP4 cells (Fig 3.9A). 
 
 Although we did not detect eIF2α phosphorylation by immunoblotting, we 
wanted to confirm that PKR activation during MERS-ΔNS4a infection does not 
mediate translation arrest in A549DPP4 cells. Thus, we compared protein synthesis 
during infection with MERS-ΔNS4a and WT MERS-CoV. We either mock infected 
or infected A549DPP4 cells with WT MERS-CoV or MERS-ΔNS4a. We treated 
cells 18 and 24 hours post-infection with puromycin for 10 minutes to label 
nascent proteins prior to protein harvest. We used immunoblotting with an anti-
puromycin antibody to specifically detect newly synthesized proteins and used 
Coomassie staining to assess total protein levels (32). Decrease in puromycin 
signal indicates translation arrest. Puromycin signal was not lower in MERS-
 98 
ΔNS4a infected A549DPP4 cells compared to WT MERS-CoV, indicating PKR 
phosphorylation did not induce downstream translation arrest (Fig 3.9B).  
 
In contrast to A549DPP4 cells, we observed no phosphorylation of PKR 
during MERS-ΔNS4a infection in 293TDPP4 cells (Fig 3.9C). Furthermore, MERS-
CoV shut down protein synthesis during infection of these cells as previously 
reported with no enhancement of translation arrest from deletion of NS4a (Fig 
3.9D) (39). This confirms the observed loss of protein synthesis occurs by an 
NS4a-independent mechanism and highlights that differences in cell type may 
affect levels of activation of the dsRNA-induced innate immune pathways. 
 
Discussion 
Studies from other labs as well as data presented herein have 
demonstrated that MERS-CoV only modestly induces three major antiviral 
pathways, IFN production and signaling, OAS-RNase L and PKR. This is likely 
due largely to viral antagonists of dsRNA-induced host responses. Our study as 
well as recent reports from other labs have shown that deletion of MERS-CoV 
accessory proteins from recombinant viruses leads to enhanced activation of 
antiviral pathways. However, these effects are relatively small compared to other 
RNA viruses, and deletion of these accessory proteins only mildly attenuates 
replication. This is in contrast to early studies utilizing overexpression and 
reporter plasmids or ectopic expression from heterologous virus studies showing 
robust suppression of IFNB induction by NS4a and NS4b (12, 13, 15, 17, 40). 
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Thus, caution is warranted in extrapolating from studies that rely only on ectopic 
expression. 
 
We have used recombinant MERS-CoV mutants to study interactions 
between the accessory proteins NS4a and NS4b and the host immune response. 
All of the viruses with mutations or deletions in NS4a and NS4b were modestly 
attenuated compared to WT MERS-CoV in A549DPP4 cells. These modest 
differences are consistent with previous studies of MERS-CoV accessory 
proteins (11, 14, 19, 35, 40). Furthermore, there is a clinical report of human 
isolates with a 16 amino acid deletion in NS4a (41)  and West African camel 
MERS-CoV isolates with ORF3 and ORF4b deletions, likely due to founder 
effects upon introduction into these populations (35). The isolation of these 
viruses supports findings that MERS-CoV accessory proteins are not definitive 
determinants of viral replication. However, all other known circulating MERS-CoV 
isolates and MERS-CoV-like viruses encode intact accessory ORFs, strongly 
suggesting that these proteins do play important roles in promoting viral fitness. 
 
 We found roles for both NS4a and NS4b in suppressing IFNL1 expression in 
response to MERS-CoV infection, which is notably muted compared to other 
RNA viruses (Fig 3.5, 3.6). The lack of a similar increase in IFNB expression in 
response to mutant MERS-CoV infection is likely due to generally less robust 
expression of IFNB in A549 cells, which preferentially express IFNL1 like other 
epithelial cells derived from barrier surfaces (42). We found that NS4b IFN 
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antagonism was dependent on nuclear localization, confirming an earlier report 
characterizing ectopically expressed NS4b (13), and its catalytic activity.   
 
 NS4b is the first viral phosphodiesterase known to suppress antiviral 
pathways in addition to RNase L, distinguishing it from phosphodiesterases 
found in the genomes of other coronavirus subgenera (Fig 3.6). While the exact 
mechanism of NS4b IFN antagonism remains unclear, several host-encoded 
PDEs within the same protein family are known or believed to participate in 
various steps of RNA processing (34, 43-49). Whether, like some cellular PDEs 
(43, 45), NS4b can cleave 3’-5’ linked phosphodiester bonds in addition to 2’-5’ 
oligoadenylates and whether it mediates any of its immune antagonist functions 
through directly or indirectly acting on host RNAs is an ongoing area of study. 
Finally, our data demonstrate that NS4b antagonism of IFN is distinct from its 
RNase L antagonist activity (Fig 3.7) demonstrating that NS4b has at least two 
independent functions.  
  
We observed reduced expression of mutant NS4b compared to WT 
protein, as we reported previously (20). It is not known whether this reduced 
expression is due to reduced protein stability or to the antibody not recognizing 
the mutant protein form as readily.  However, the abundance of NS4b during 
infection with MERS-NS4bNLSmut, though lower than WT protein, is sufficient to 
fully prevent RNase L activation, indicating mutation does not reduce NS4b 
levels below an effective concentration (Fig 3.7) (24, 38, 50). Thus, it is unlikely 
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that decreased mutant protein abundance is responsible for the observed IFN 
phenotype (25). We consistently observed a faster migrating band staining with 
antiserum directed against NS4b (Fig 3.1C).  We presume that this band is less 
easily detected in the NS4b mutants due to the lower expression level and 
because this faster band is already faint in the WT MERS-CoV NS4b. We do not 
know the identity of this band. However, we speculate it could be a breakdown 
product of full length NS4b or more interestingly a protein initiated at one of 
several ATGs located downstream and in frame with the NS4b initiation site.	
 
Activation of RNase L during MERS-NS4bH182R infection is less robust than 
during infection with MHV-NS2H126R in macrophages (24) or SINV infection of 
A549 cells (Fig 3.7) (31), suggesting MERS-CoV may have redundant 
mechanisms for inhibiting this pathway. Based on the role of the viral dsRNA 
binding proteins NS1 of Influenza and E3L of Vaccinia virus (22, 23, 37) in 
blocking RNase L activation as well as IFN and PKR, we hypothesized that NS4a 
contributes to antagonism of OAS-RNase L. Surprisingly, infection with MERS-
ΔNS4a did not induce increased rRNA degradation compared to wild-type virus, 
nor did NS4a deletion produce any additive effect on RNase L activation in 
combination with deletion of NS4b. Nevertheless, the lack of robust RNase L 
activation even when NS4b is catalytically inactive suggests the possibility 
MERS-CoV does encode additional antagonists. One intriguing possibility is 
nsp15; its MHV ortholog has recently been described as contributing to evasion 
of multiple dsRNA-sensing pathways (51, 52). Alternatively, as has been 
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speculated for MHV, MERS-CoV dsRNA may, even in the absence of NS4a, be 
contained in viral replication/transcription complexes (RTCs) and therefore 
hidden from antiviral sensors (53, 54). 
 
Due to its dsRNA-binding activity, we also hypothesized that NS4a inhibits 
PKR activation. One previous study showed that ectopically expressed NS4a 
inhibits PKR activation and can functionally replace the native PKR antagonist of 
encephalomyocarditis virus (40). Deletion of NS4a within recombinant MERS-
CoV has previously been shown to result in enhanced translation arrest 
compared to WT MERS-CoV in HeLa cells (19). Consistent with this, we found 
that deletion of NS4a results in PKR phosphorylation, but in A549DPP4 cells this 
did not lead to phosphorylation of eIF2α above background levels, and MERS-
ΔNS4a did not induce more translation arrest than WT MERS-CoV. In 293TDPP4 
cells, MERS-CoV induced translation arrest as previously reported (39), but we 
did not observe a more robust effect during MERS-ΔNS4a infection. 
Furthermore, PKR was not phosphorylated in 293TDPP4 cells during MERS-
ΔNS4a infection, confirming the PKR-independent mechanism of translational 
arrest and highlighting differences between cell types in antiviral pathway 
activation. These differences demonstrate the importance of using multiple model 
systems to fully elucidate interactions between viral proteins and host immune 
pathways. 
 
 103 
Despite the lack of robust replication phenotypes, studies of MERS-CoV 
accessory proteins from other labs as well as our own have identified novel and 
important virus-host interactions that likely contribute in important ways to 
maintenance of MERS-CoV in its ecological niche and possibly during infection 
of the human respiratory tract. Future work on MERS-CoV accessory proteins in 
animal models and in vitro systems that more faithfully recapitulate the human 
airway should more fully answer the question of how these proteins contribute to 
replication under immune pressure and to pathogenesis. 
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Introduction 
My published work on the MERS-CoV NS4b accessory protein, described 
in Chapter 4 and Thornbrough et. al. (1) has identified it as a phosphodiesterase 
with both conserved and unique interactions with host innate immunity. As with 
other viral phosphodiesterases (2-4), NS4b antagonizes the OAS-RNase L 
antiviral pathway through cleavage of the RNase L-activating second messenger 
2-5A (5, 6). Additionally, we demonstrated as described in Chapter 4 that 
mutation of either the catalytic site or nuclear localization sequence (NLS) of 
NS4b results in elevated interferon (IFN) and interferon-stimulated gene (ISG) 
expression. However, we have so far not determined the mechanism by which 
NS4b modulates the abundance of IFN and ISG transcripts, whether through the 
inhibition of transcription or some interference at the co-transcriptional or post-
transcriptional level. Earlier studies of NS4b have suggested it may be able to 
prevent IFN gene expression (7, 8), but the mechanism of doing so and 
particularly the involvement of its catalytic activity has not been well studied.  
 
We have determined that while some reports describe ectopically 
expressed NS4b as blocking nuclear translocation of interferon regulatory factor-
3 (IRF3) (7, 8), a critical transcription factor for IFN gene expression, mutation of 
the NS4b catalytic site or NLS does not result in increased IRF3 phosphorylation 
and we likewise did not detect any increase in IRF3 nuclear accumulation during 
MERS-CoV infection (Fig 4.1). Having excluded this possibility, we sought to 
draw on the literature describing other members of the 2H-phosphoesterase (2H-
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PE) superfamily of phosphodiesterases (PDEs), the superfamily that includes the 
coronavirus PDEs, in order to generate hypotheses regarding the mechanistic 
interactions between NS4b and the host. This literature, reviewed briefly below, 
clearly indicates that the characterized functions of 2H-PE almost uniformly 
involve some element of RNA processing though the function is not known for 
every member of the superfamily.   
 
Known functions of cellular 2H-phosphoesterases 
2H-phosphoesterases are nearly ubiquitous among cellular life forms and 
are believed to have been present in the last universal common ancestor of all 
modern life, though they have been lost in some bacterial lineages (9). Within the 
2H-phosphoesterase superfamily are several families. These include the 
prototypical archaeo-bacterial LigT group, the eukaryotic-viral LigT-like group 
(including MHV NS2 and MERS-CoV NS4b), the bacterial Yjcg-like group, and 
the mlr3352-like group from bacteria but which also appears in the genomes of 
some large eukaryotic DNA viruses, likely as a result of horizontal gene transfer 
(9). In addition, several 2H-phosphoesterases do not fit neatly within any of these 
groups, such as the 2’,3’ cyclic nucleotide phosphodiesterases found in the 
nervous system of vertberates and a group of enzymes encoded by retroviruses 
of fish (9-11). 
 
The prototypical member of the LigT-like family of 2H-phosphoesterases is 
the E. coli LigT protein, evidence of which was first identified through the 
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observation of 2’,5’ RNA ligase activity in an E. coli extract, then purified and 
cloned (9, 12-14). LigT can both catalyze and break 2’,5’ linkages between tRNA 
halves. Proteins with similar activity have also been identified in 
hyperthermophilic archaea of the genus Pyrococcus (15), as well as in fungi and 
the bacteriophage T4 (9).  The presence of genes encoding archaeo-bacterial 
LigT-like proteins in fungal genomes likely is explained by virus-mediated cross-
kingdom horizontal gene transfer (HGT) between prokaryotes and fungi (9). 
Although such cross-kingdom HGT has historically been considered unlikely or 
rare, recent evidence suggests otherwise (16, 17). 
 
Among eukaryotes, LigT-like 2H-PEs are also ubiquitous and may best 
inform predictions about the function of the viral 2H-PEs they are presumably 
ancestral to. Prior to the discovery of LigT-like 2H-PEs in eukaryotes, 2’,3’ cyclic 
nucleotide phosphodiesterases (CPDases), a divergent family of 2H-
phosphoesterases, were identified as active in tRNA ligation in yeast and in the 
nervous system of complex eukaryotes, including humans (10, 18-20). Although 
the RNA ligase domain of these proteins is similar to that of archaeo-bacterial 
LigT-like proteins, they belong to a distinct family. In contrast, eukaryotes and 
some of their viruses encode LigT-like 2H-PEs that have distinct functions 
unrelated to tRNA ligation.  
 
The eukaryotic-viral LigT-like 2H-PEs are typified by the human CGI-18 
gene, also known as the ASCC1 subunit of  activating signal co-integrator 
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complex 1 (ASC-1) (9, 21, 22). Although CGI-18 is the family prototype, relatively 
little is known about its function within ASC1, though interest has grown recently 
as truncating mutations of CGI-18 have been associated with a range of genetic 
diseases (23, 24). One report has demonstrated a critical role for the catalytic 
histidines of CGI-18 in regulating its localization within the nucleus (25), but an 
enzymatic substrate or function for CGI-18 remains unidentified. Another of the 
cellular LigT-like 2H-PEs, a-kinase anchoring protein-18 (AKAP18), has been 
more extensively studied than CGI-18 although the physiological significance of 
its enzymatic activity is likewise not known. AKAP18 in fact refers to several 
isoforms of the same protein expressed from a single AKAP7 gene, and only two 
of the 4 isoforms (γ and δ) contain a central PDE domain (26, 27). The AKAP18 
PDE, like MHV NS2 and MERS-CoV NS4b, has 2’,5’ PDE activity and it or a 
similar gene may be ancestral to the viral PDEs, though the degree of sequence 
divergence aside from the conserved catalytic motifs makes this currently 
impossible to determine. Bolstering this possibility, however, is that the known 
MHV NS2 and rotavirus VP3 CTD structures and predicted MERS-CoV NS4b 
structure are most similar to that of the AKAP18 central domain, more so than to 
other eukaryotic 2H-PE known structures or of bacterial LigT (1, 28). AKAP18 
anchors protein kinase A to cellular membranes and binds to cAMP and 
experimental evidence demonstrates that AKAP18γ and δ isoforms regulate PKA 
activity, however whether it has a catalytic substrate and what that may be is 
unknown (26, 29, 30).  
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Unlike AKAP18 and CGI-18, the physiological role of the eukaryotic 2H-
PE USB1 is well understood. As is true for the prokaryotic LigT-like 2H-PEs, 
USB1 participates in RNA processing. Specifically, USB1 of both yeast and 
humans associates with the spliceosome and is essential for processing of the 
U6 snRNA. USB1 is a 3’-5’ exonuclease that removes Us and As from the 3’ 
prime end of U6 and catalyzes the formation of a 2’,3’ cyclic phosphate that 
protects U6 from exosomal degradation (31-33). Although USB1 was first 
recognized as removing uridines from the 3’ end of U6, it actually has a higher 
level of activity against in vitro oligoA substrates, which is consistent with 
observations that a lack of USB1 leads to aberrantly 3’ polyadenylated U6, 
decreased stability of the snRNA, and consequent defects in splicing (31, 33-35). 
It is not known whether USB1, like AKAP18 and viral 2H-PEs, has 2’,5’ PDE 
activity in addition to the 3’,5’ activity necessary for its post-transcriptional 
processing of U6, though this is an active area of investigation in collaboration 
with Dr. Robert Silverman of the Cleveland Clinic. 
 
Given the extensive demonstrated involvement of cellular 2H-PEs in RNA 
metabolism, and after determining that NS4b does not participate in IRF3 
inhibition during infection through its catalytic domain or NLS (Fig 4.1), we 
hypothesized that it may modulate antiviral responses through participation in 
RNA processing. Our initial hypothesis was that NS4b might, like USB1, have 3’-
5’ exonuclease activity that would allow it to shorten mRNA poly(A) tails, resulting 
in accelerated turnover. However, mutation of neither the NS4b catalytic site nor 
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nuclear localization sequence resulted in reproducible changes in the decay 
rates of several antiviral mRNAs, as measurable by the RT-qPCR assay we used 
(Fig 4.2). In collaboration with Dr. Robert Silverman, we are continuing to 
investigate the substrate range of MERS-CoV NS4b and other 2H-PEs. We 
previously demonstrated that it has 2’,5’ PDE activity (1), but do not yet now if it 
can act on other types of phosphodiester linkages as well. Most recently, we 
have developed preliminary evidence that NS4b may participate in the splicing 
process. Infection with MERS-NS4bH182R or MERS-NS4bNLSmut results in elevated 
abundance of IFNL1 and ISG mRNAs (Fig 3.6). In addition, during infection with 
MERS-NS4bH182R but not MERS-NS4bNLSmut the abundance of some intronic 
RNA is increased relative to during WT MERS-CoV infection. Post-splicing, 
branched intron lariats contain a 2’,5’ phosphodiester linkage that must be 
cleaved so that the intron can be degraded and the nucleotide pool replenished. 
The cellular enzyme DBR1 is responsible for lariat debranching (36), and we 
hypothesized that NS4b may accelerate this process during infection to prevent 
accumulation of circular intron-derived RNAs due to virus-induced transcriptional 
increases (37), though the possible impact of such accumulation remains 
unknown. Future studies will more extensively investigate this observation and 
seek to uncover the underlying mechanism. Nevertheless, though preliminary, 
these data suggest that, like cellular 2H-PEs but unique among viral PDEs, 
MERS-CoV may participate in cellular RNA metabolism. 
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Materials and Methods 
 
Recombinant viruses. Recombinant WT MERS-CoV and mutants were derived 
from the EMC/2012 strain cDNA clone by Dr. Ralph Baric, all by introducing 
mutations into cDNA fragment F assembling the genome fragment and 
recovering infectious virus as described previously (38). 
 
MERS-NS4bH182R was previously described (20). MERS-4bNLSmut was 
constructed by substituting residues 31, 33, 36, 37, 38 and 43 each with 
alanine.  Briefly, one PCR product was generated using primers 
MERS:F1376 (5’-GTTTCTGTCGATCTTGAGTC-3’) and MERS4bR (5’-
NNNNNNCGTCTCGCAACGTAGGCCAGTGCCTTAGTTGGAGAATGGCTCCTC
-3’).  A second PCR reaction was performed with the primers MERS4bF (5’-
NNNNNNCGTCTCCGTTGCGGCTGCATTTTCTCTTCTGGCCCATGAAGACCT
TAGTGTTATTG-3’) and MERS:F3415 (5’-GAGGGGGTTTACTATCCTGG-
3’). The position of the F1376 primer in context of the MERS genome is 25,748-
25,767, while the position for the reverse F3415 primer is 27,815-27,796. The 
products were gel isolated, digested with BsmBI (underlined in the above 
primers) and ligated with T4 DNA ligase.  The resultant product was digested 
with PacI and SanDI, gel purified, and then used to replace the corresponding 
region in the MERS F plasmid which had been similarly digested.   All 
recombinant viruses were isolated as previously described (38). 
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Cell lines. A549DPP4 cells were constructed by lentivirus transduction of DPP4. 
The plasmid encoding the cDNA of DPP4 was purchased from Sino Biological. 
The cDNA was amplified using forward primer: 
5’-GACTCTAGAATGAAGACACCGTGGAAGGTTCTTC-3’ and reverse primer: 
5’-
TCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCAGGTAAAGAGAAACAT
TGTTTTATG-3’. A V5 tag was introduced to the 3’ end of the cDNA by PCR to 
enable easy detection of DPP4. The amplicon was cloned into pCR4-TOPO TA 
cloning vector (Invitrogen #K457502), to make pCR4-DDP4-V5. The fragment 
containing DPP4-V5 was digested by XbaI/SalI restriction enzymes from the 
pCR4-DPP4-V5 and was cloned into pLenti-GFP in place of GFP, generating 
pLenti-DPP4-V5. The resulting plasmids were packaged in lentiviruses 
pseudotyped with VSV-G to establish the gene knock in cells as previously 
described (39). Forty-eight hours after transduction cells were subjected to 
hygromycin (1mg/ml) selection for 3 days and single-cell cloned. Clones were 
screened for DPP4 expression and susceptibility to MERS-CoV replication.  
 
MERS-CoV infections. Viruses were diluted in serum-free RPMI and added to 
cells for absorption for 45 minutes at 37°C. Cells were washed three times with 
PBS and fed with RPMI+2% FBS. RNA was harvested at indicated hours post-
infection by lysing cells with Qiagen buffer RLT Plus and isolating RNA using the 
RNeasy Plus kit (Cat #: 74136) and provided protocol. All infections and virus 
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manipulations were conducted in a biosafety level 3 (BSL3) laboratory using 
appropriate personal protective equipment and protocols. 
 
Western immunoblotting. Cells were washed twice with ice-cold PBS and lysed 
with lysis buffer (1% NP40, 2mM EDTA, 10% glycerol, 150mM NaCl, 50mM Tris 
HCl) supplemented with protease inhibitors (Roche – cOmplete mini EDTA-free 
protease inhibitor) and phosphatase inhibitors (Roche – PhosStop easy pack). 
Lysates were incubated on ice for 20 minutes, centrifuged for 20 minutes at 4°C 
and supernatants mixed 3:1 with 4x Laemmli sample buffer. Samples were 
heated at 95°C for 5 minutes, then separated on 4-15% SDS-PAGE, and 
transferred to polyvinylidene difluoride (PVDF) membranes. Blots were blocked 
with 5% BSA and probed with the following antibodies diluted in 5% BSA at 
1:1000 dilution: rabbit anti-IRF3 mAb D83B9 (Cell Signaling Technologies Cat #: 
4302), rabbit anti-phospho-IRF3 mAb (Abcam Cat #: 76493), anti-MERS N 
mouse mAb (SinoBiological Cat #: 40068-MM10), anti-GAPDH rabbit mAb 
14C10 (Cell Signaling Technology Cat #: 2118). Secondary antibodies used 
were: Santa Cruz goat anti-mouse IgG-HRP secondary antibody (Cat #: SC2005) 
at 1:5000 and Cell Signaling Technology anti-rabbit IgG, HRP-linked secondary 
antibody (Cat #: CS7074) at 1:3000. Blots were visualized using Thermo 
Scientific SuperSignal west chemiluminescent substrates (Cat #: 34095 or 
34080). Blots were probed sequentially with antibodies and in between antibody 
treatments stripped using Thermo scientific Restore western blot stripping buffer 
(Cat #: 21059). 
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Immunofluorescent staining. At indicated times post-infection cells were fixed 
with 4% paraformaldehyde for 30 minutes at room temperature. Cells were then 
washed three times with PBS and permeabilized for 10 minutes with PBS+0.1% 
Triton-X100. Cells were then blocked in PBS and 2% BSA for 45-60 minutes at 
room temperature. Primary antibodies were diluted in block buffer and incubated 
on a rocker at room temperature for one hour. Cells were washed three times 
with block buffer and then incubated rocking at room temperature for 30 minutes 
with secondary antibodies diluted in block buffer. Finally, cells were washed twice 
with block buffer and once with PBS, and nuclei stained with DAPI diluted in 
PBS. Coverslips were mounted onto slides for analysis by widefield microscopy. 
Proteins of interest were detected using primary antibodies (1:1000 dilution) 
rabbit anti-IRF3 mAb D83B9 (Cell Signaling Technologies Cat #: 4302), anti-
MERS N mouse mAb (SinoBiological Cat #: 40068-MM10). Secondary 
antibodies were all highly cross-adsorbed IgG (H+L) from Invitrogen: Goat-anti 
rabbit AF594 (Cat #: AA11037), goat anti-mouse AF488 (Cat #: AA11029). 
 
Quantitative real time PCR (qRT-PCR). At indicated times post-infection cells 
were lysed with Qiagen Buffer RLT Plus (Cat #: 74136) and RNA extracted 
following the prescribed protocol. cDNA was synthesized according to the 
protocol for Thermo Scientific Superscript III reverse transcriptase (Thermo 
Scientific #18080044). RT-qPCR was performed under conditions validated for 
the indicated primer set. Primer sequences are as follows: IFIT2-exonic (F: 5’ - 
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CTGAGAATTGCACTGCAACCATG - 3’, R: 5’-
TCCCTCCATCAAGTTCCAGGTGAA-3’), IFIT2-intronic (F: 5’- 
TGTCCAATGCAAATCCTGAGAAGC 
-3’, R: 5’- AAATGGAGCTGGCCCTCTTTGG-3’) GAPDH-exonic (F: 5’-
GCAAATTCCATGGCACCGT-3’, R: 5’-TCGCCCCACTTGATTTTGG-3’), 
GAPDH-intronic (F: GACCTTTACTCCTGCCCTTTGA-3’, R: 5’-
TGGTATTCACCACCCCACTATG-3’), DDX58-exonic (F: 5’- 
TAGCTCAGCTGATGAGGGACAC-3’, R: 5’-CTTTGTCTGGCATCTGGAACAC-
3’), DDX58-intronic (F: 5’-AAAGTCCGGCTCCTCTCCAGCTT-3’, R: 5’- 
GTCCAAGGGATGGGACACAAAGG-3’), 18S rRNA (F: 5’- 
TTCGATGGTAGTCGCTGTGC-3’, R: 5’- CTGCTGCCTTCCTTGAATGTGGTA 
-3’. Fold changes in mRNA over mock-infected cells were calculated using the 
formula 2-∆(∆Ct)(ΔCt = Ctgene of interest – CtGAPDH) and expressed as fold 
infected/mock-infected. To calculate RNA abundance for experiments measuring 
mRNA decay, I first calculated the amount of RNA relative to the highly stable 
18S mRNA using the formula 2-∆Ct, with the 0 hour time point set as 1. I then 
calculated mRNA remaining by dividing the relative mRNA level (to 18S) at later 
time points by the relative RNA level at the 0 hour time point.  
 
Statistical analysis. Plotting of data and statistical analysis were performed 
using GraphPad Prism software (GraphPad Software, Inc., CA). Statistical 
significance for RT-qPCR was determined by application of an unpaired student’s 
t-test, with a significance threshold of p>0.05. 
 123 
 
Results 
 
Mutation of NS4b does not alter IRF3 activation. Previous studies have 
demonstrated that ectopically expressed NS4b inhibits nuclear accumulation of 
IRF3, a critical antiviral transcription factor, contributing to its IFN antagonism (7, 
8, 40). To determine whether the elevated IFN and ISG mRNA levels induced by 
MERS-NS4bH182R and MERS-NS4bNLSmut are linked to increased activation of 
IRF3, I infected A549DPP4 cells with these viruses 
and WT MERS-CoV at MOI=5 and assayed for 
IRF3 phosphorylation by western blot and nuclear 
localization by immunofluorescent microscopy. I 
used Sendai virus (SeV) as a positive control for 
IRF3 phosphorylation and nuclear translocation, as 
it is a known potent inducer of IFN (Fig 3.5). SeV-
infected A549DPP4 cells were lysed for protein 
extraction 12 hours post-infection (hpi), 
while MERS-CoV infected cells were lysed 
24 and 36 hpi. Only SeV induced the 
appearance of detectable phospho-IRF3 
(Fig 4.1), despite modest IFN induction by 
MERS-NS4bH182R and MERS-NS4bNLSmut that presumably require some low 
Figure 4.1. WT and NS4b mutant MERS-
CoV do not induce IRF3 phosphorylation. 
A549DPP4 cells were mock infected or infected 
at MOI=5 with Sendai virus (SeV), WT 
MERS-CoV, MERS-NS4bH182R, or MERS-
NS4bNLSmut. Cells were lysed for protein 
harvesting at the indicated times post-
infection and proteins separated by SDS-PAGE 
and immunoblotted with antibodies against 
phospho-IRF3, IRF3, MERS-CoV nucleocapsid, 
or GAPDH. Data are representative of two 
independent experiments. 
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amount of IRF3 activation, though IFN activation through another transcription 
factor may be possible. 
 
To confirm that 
mutation of the NS4b 
catalytic site or NLS 
does not affect IRF3 
activation, I quantified 
IRF3 nuclear 
localization during SeV, 
WT MERS-CoV, and 
mutant NS4b MERS-
CoV infection. SeV-
infected A549DPP4 cells 
were fixed with 4% PFA 
12 hpi, while MERS-
CoV infected cells were 
fixed 24 hpi. I then 
stained the fixed cells 
with an anti-IRF3 
monoclonal antibody 
and quantified the 
florescent intensity of 
Figure 4.2. WT and NS4b mutant MERS-CoV do not induce nuclear 
localization of IRF3. A549DPP4 cells were mock infected or infected at 
MOI=5 with Sendai virus (SeV), WT MERS-CoV, MERS-NS4bH182R, or 
MERS-NS4bNLSmut. At either 12 (SeV), or 24 hours post-infection cells 
were fixed and stained with DAPI and antibodies against IRF3, and 
either SeV nucleoprotein or MERS-CoV nucleocapsid and secondary 
antibody goat anti-rabbit AF594 or goat anti-mouse AF488. A) Cells were 
analyzed by widefield microscopy and images processed in ImageJ. B) and 
C) In ImageJ, nuclei were defined and cells classified as uninfected or 
infected based on the presence of viral antigen signal above background. In 
each nucleus, the mean or maximum gray value of IRF3 fluorescent signal 
was measured. Quantification was based on at least 50 cells for each 
condition, and statistical significance calculated by unpaired student’s t-test. * 
p ≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. 
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IRF3 in the nuclei of infected and uninfected cells. Antibodies against Sendai 
virus nucleoprotein (NP), and MERS-CoV nucleocapsid (N) were used in 
conjunction with the anti-IRF3 antibody to identify infected cells. Only Sendai 
virus induced a statistically significant increase in average or maximum IRF3 
fluorescent intensity in the nucleus (Fig 4.1B-D).  
 
Mutation of MERS-CoV NS4b does not alter antiviral mRNA stability. Based 
on the extensive involvement of 2H-PEs in RNA processing (9) and the 3’-5’ 
deadenylating activity of eukaryotic 
2H-PE USB1(34), we sought to 
determine whether NS4b destabilizes 
host antiviral mRNAs. I infected 
A549DPP4 cells with either WT MERS-
CoV, MERS-NS4bH182R, and 
MERS-NS4bNLSmut at MOI=5 and 
at 24 hpi treated the cells with 5 
µg/ml actinomycin D to arrest 
transcription as described in the 
literature. (41, 42). At 0 and 8 
hours post-actinomycin D 
treatment I harvested RNA from infected cells. I then used qRT-PCR to quantify 
the amounts of indicated antiviral mRNA relative to the first RNA harvest time 
point to assay for the percentage amount of mRNA remaining as an indirect 
Figure 4.3. Mutation of MERS-CoV NS4b does not alter 
antiviral mRNA stability. A549DPP4 cells were infected at MOI=5 
with WT MERS-CoV, MERS-NS4bH182R, or MERS-NS4bNLSmut. 
24 hours post-infection, media was replaced with fresh media + 5 
µg/ml actinomycin D. I then waited one hour to ensure full 
transcriptional arrest, and lysed cells for RNA extraction and 
designated this as time 0. 8 hours later, a second set of cells 
were lysed for RNA extraction. The abundance of indicated 
RNAs was analyzed by qRT-PCR. To calculate RNA 
abundance for experiments measuring mRNA decay, I first 
calculated the amount of RNA relative to the highly stable 
18S mRNA using the formula 2-∆Ct, with the 0 hour time point 
set as 1 (or 100%).The fraction of mRNA remaining after 8 
hours was calculated by dividing the relative mRNA level (to 
18S) at later time points by the relative RNA level at the 0 
hour time point.  
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measure of mRNA degradation. At 8 hours post-treatment I compared the 
percentage of mRNA remaining between WT MERS-CoV, MERS-NS4bH182R, and 
MERS-NS4bNLSmut. I did not observe any apparent difference in antiviral mRNA 
decay during infection with the WT or NS4b mutant viruses (Fig 4.3), suggesting 
that MERS-CoV NS4b does not induce accelerated decay of antiviral mRNAs, 
and thus this putative mechanism does not likely account for the previously 
observed increase in the abundance of such mRNAs during infection with MERS-
NS4bH182R and MERS-NS4bNLSmut.  
 
Ablation of MERS-CoV NS4b catalytic activity results in increased 
abundance of intronic RNA. After I did not observe any changes in mature 
mRNA stability due to 
mutation of NS4b, I sought to 
determine if NS4b is involved 
in post-transcriptional RNA 
processing during or after 
splicing. To do so, I utilized 
two schemes for qRT-PCR 
analysis. The first aimed at 
quantification of mature 
antiviral mRNA using primers 
amplifying across exon-exon 
junctions, as described in Chapter 3 and typically used for gene expression 
Figure 4.4. Ablation of MERS-CoV NS4b catalytic activity 
results in increased abundance of intron-derived RNA. 
A549DPP4 cells were infected at MOI=5 with WT MERS-CoV, 
MERS-NS4bH182R, or MERS-NS4bNLSmu. 24 hours post-infection 
cells were lysed and RNA extracted for analysis by qRT-PCR. 
RNA harvested at the indicated times post-infection. Gene 
expression over mock-infected cells was measured by RT-qPCR 
and calculated over mock-infected cells using the 2-Δ(ΔCT) formula. 
Data are from one representative of three independent 
experiments and expressed as mean ± SEM. Statistical 
significance was determined by unpaired student’s t-test;  * p 
≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. 
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quantification. For the second, I used primers targeting introns, which can detect 
both unspliced pre-mRNAs and introns excised during the splicing reaction but 
not yet debranched and degraded (Fig 4.4).  
 
 I infected A549DPP4 cells with WT MERS-CoV, MERS-NS4bH182R, MERS-
NS4bNLSmut at MOI=5 and harvested RNA 24 and 36 hpi. I then used qRT-PCR 
with primers targeting exonic and intronic regions of RNAs transcribed from the 
ISGs IFIT2 and DDX58, as well as an intron of the metabolic gene GAPDH. As 
seen during previous experiments (Fig 3.6), the abundance of mature IFIT2 
mRNA was elevated during MERS-NS4bH182R and MERS-NS4bNLSmut infection 
relative to during WT MERS-CoV infection, while DDX58 mature mRNA levels 
were generally not induced by MERS-CoV infection (Fig 4.4), though DDX58 can 
be induced in these cells by treatment with high concentrations of recombinant 
IFN (not shown). GAPDH intron RNA levels did not differ between infection with 
WT or NS4b mutant MERS-CoV (Fig 4.4). In contrast, IFIT2 and DDX58 intronic 
RNA was more abundant during MERS-NS4bH182R infection than during infection 
with WT MERS-CoV or MERS-NS4bNLSmut (Fig 4.4). It remains unclear where the 
targeted intron is more abundant because it is retained in the mRNA are 
increased frequencies or if the excised lariat is more stable, as attempts to 
quantify IFIT2 and DDX58 pre-mRNA were unsuccessful. 
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Discussion 
I did not find that mutation of the MERS-CoV NS4b catalytic site or NLS 
resulted in increased activation of the critical antiviral transcription factor IRF3 
(Fig 4.1). Previous studies found that ectopically expressed NS4b inhibits nuclear 
translocation of IRF3 (7, 40). A later study likewise showed that NS4b blocks 
IRF3 nuclear translocation, as well as IRF3 phosphorylation and prevented 
luciferase expression from an IFNB promoter following ectopic expression of 
IRF3 (8). Notably, this study found that removal of the NS4b NLS abrogated the 
ability of NS4b to block IRF3-induced IFNB promoter expression.  
 
The apparent conflict between these reports and my work may be 
explained by one or multiple factors. Some differences could be accounted for by 
the use of ectopically expressed NS4b, which may produce results that do not 
faithfully recapitulate physiological interactions during infection. Specifically, 
ectopic expression can result in intracellular concentrations well above 
physiological levels, which may allow for protein-protein interactions that don’t 
occur during infection but would disrupt signaling pathways. Another possibility is 
that inhibition of IRF3 activation is mediated by regions of NS4b unaffected by 
the mutations in the recombinant viruses I used. A 2015 report by Yang et. al. 
suggested that cytoplasmic NS4b interferes with the assembly of the MDA5 
signaling complex activated in response to viral dsRNA and upstream of IRF3. 
This function is unlikely to be affected by mutations deep within the NS4b 
catalytic domain and was found in that study to be independent of the NLS, as N-
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terminal truncated NS4b still disrupted MDA5 signaling (8). If confirmed during 
MERS-CoV infection, this would suggest yet another immune antagonist function 
for NS4b, which has already been identified as inhibiting RNase L activation (1), 
NFκB nuclear translocation (43), and the IFN response through a catalytic 
mechanism independent of RNase L (Chapter 3).  
 
 Two factors drove our hypothesis that NS4b innate immune antagonism 
likely includes an involvement in RNA processing. One is the extensively 
documented involvement of cellular 2H-PEs in diverse steps of RNA processing, 
including splicing (9, 34, 44). The second was our observation that NS4b IFN 
antagonism is dependent on its catalytic activity, suggesting its interaction with 
the IFN response goes beyond any protein-protein interaction (Fig 3.5). We 
previously described MERS-CoV NS4b as exhibiting 2’,5’ PDE activity (1), but 
the question of whether it can bind to and cleave other substrates remains under 
investigation. The AKAP7 PDE similarly binds to and cleaves the linear 2-5A 
molecule, but also binds cAMP (26, 27, 45). The eukaryotic 2H-PE USB1 exhibits 
3’,5’ PDE activity and removes uridines and adenosines from the 3’ end of the U6 
snRNA (31, 34, 44). Assessing that NS4b might exhibit similar 3’,5’ exonuclease 
activity, we tested whether it accelerates mRNA decay, which could occur as a 
result of 3’ deadenylation. My experiments testing this hypothesis did not 
demonstrate any effect of NS4b on mRNA turnover, and whether NS4b can 
target substrates other than 2-5A, such as 3’,5’ phosphodiester bonds, remains 
an area of active inquiry with our collaborator Robert Silverman of the Cleveland 
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Clinic. Should NS4b prove to have 3’,5’ PDE activity, it would be worthwhile to re-
examine whether it can target mRNAs 
 
 Noting the demonstrated 2’,5’ PDE activity of MERS-CoV NS4b, we 
considered that it might act on 2’,5’ linked substrates other than 2-5A. One such 
cellular substrate is the intronic lariat formed as a byproduct of the splicing 
reaction (36). I found that intronic RNA is more abundant during MERS-
NS4bH182R infection than during infection with WT MERS-CoV or MERS-
NS4bNLSmut (Fig 4.4), specifically the sole intron from IFIT2, and the first intron 
from the much larger DDX58 gene. One possible explanation is that NS4b 
disrupts splicing in some way and that the introns are retained within the mRNA. 
Retained introns within the gene body typically lead to nonsense mediated decay 
(NMD) of the mRNA (46-48), so in this scenario the IFIT2 and DDX58 mRNAs 
are unlikely to be translated. My attempts to quantify IFIT2 and DDX58 mRNAs 
with retained introns (or pre-mRNA) using primers spanning exon-intron 
boundaries were unsuccessful due to apparent low abundance of such 
transcripts, but this explanation for the increased intron signal during MERS-
NS4bH182R infection seems unlikely. One reason for this is my inability to reliably 
quantify intron-containing mRNAs even during viral infection, in contrast with the 
robust signal obtained by using primers targeted solely within the intron. A 
second reason is that if intron retention explained the observation, it would mean 
mutation of an innate immune antagonist results in an increase in non-functional 
mRNA, while selective pressure seems more likely to result in a scenario wherein 
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NS4b mutation would lead to a more effective immune response. Nevertheless, it 
remains important that future studies be designed to test this possibility. 
 
 A second, more likely possibility, is that the elevated intron signal is due to 
slower lariat degradation during MERS-NS4bH182R infection than during infection 
with WT MERS-CoV or MERS-NS4bNLSmut. Lariat degradation is initiated by the 
cellular 2’,5’ PDE DBR1 (36, 37), but some recent evidence suggests a 
significant number of lariats can escape debranching and accumulate in the 
cytoplasm (37). The physiological consequence of circular RNA accumulation, 
intron-derived or not, remains unclear. However, it is widely recognized that the 
accumulation of unusual nucleic acid molecules can trigger a variety of antiviral 
pathways via sensors such as cGAS (49-51), RIG-I (52, 53), and MDA5 (54-56). 
It is possible that unusual accumulation of lariats may serve as a yet-
uncharacterized signal or amplifier of innate immune activation, though such a 
hypothesis lacks preliminary supportive data and requires significant work to 
substantiate. Our ongoing efforts to identify a physiological impact of lariat 
accumulation and the role of NS4b in determining intron fate, before or after 
splicing, will be further discussed in the General Discussion (Chapter 5). 
 
 Although we have not yet elucidated the mechanisms of NS4b interactions 
with the IFN response, my work described in Chapter 3 and this chapter 
demonstrates a novel role for viral 2H-PEs. Notably, while NS4b has been 
previously described as inhibiting elements of the innate immune response other 
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than RNase L such as NFκB (43) and IFN induction (7, 8, 40, 57), a role for the 
NS4b catalytic PDE domain, or that of any viral 2H-PE, outside of antagonizing 
RNase L was previously unknown. Through the unpublished work described in 
this chapter I have generated preliminary mechanistic insights into this novel role, 
in that NS4b appears to affect the fate of host introns which is consistent with the 
recognized role of cellular 2H-PEs in RNA processing. Future work, discussed in 
Chapter 5, will focus on fully characterizing this interaction and exploring the 
consequences of lariat accumulation.  
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Introduction 
Through my thesis work I have both expanded the Weiss laboratory’s 
previous contributions to our understanding of virus-RNase L interactions, and 
expanded our knowledge of how viral phosphodiesterases regulate antiviral 
responses more broadly. RNase L-mediated cleavage of viral and cellular RNA is 
a long-known, critical mechanism of antiviral defense against such diverse 
pathogens as picornaviruses, orthomyxoviruses, reoviruses, togaviruses, 
flaviviruses, poxviruses, and retroviruses (1). Not unexpectedly, many of these 
viruses encode proteins that potently inhibit RNase L activation such as poxvirus 
E3L and D9 (2-4), influenza A virus NS1 (5), and Theiler’s murine 
encephalomyelitis L* (6, 7). Other viruses targeted by RNase L, such as Sindbis 
virus and West Nile virus lack a known RNase L antagonist and their replication 
is significantly enhanced when RNase L is not present (8-10). Coronavirus 
interactions with the OAS-RNase L pathway were largely unknown prior to a 
2012 Weiss laboratory study by Zhao et. al. (11). The mouse hepatitis virus 
(MHV) NS2 protein, the prototypical coronavirus RNase L antagonist, was 
computationally assessed as a phosphodiesterase in 2002 (12), though its 
importance for MHV innate immune antagonism was discovered later (13) and its 
specific inhibition of RNase L later still (11). This characterization included 
biochemical studies that revealed MHV NS2 as an unusual 2’,5’-specific 
phosphodiesterase (11), setting the stage for the continued studies of 
coronavirus-RNase L interactions that constituted my early dissertation studies. 
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Coronavirus phosphodiesterases and RNase L 
Chapter 2 of this thesis describes work involving several members of the 
Weiss laboratory that significantly expand the scope of interactions between 
coronaviruses and the OAS-RNase L pathway. The first such interaction to be 
characterized was that mediated by MHV NS2. Initially, NS2 was believed 
dispensable for coronavirus replication (14) due to studies being conducted in 
cell lines that generally lack effective antiviral responses, or in the central 
nervous system where RNase L is also not active. Once recombinant MHV 
studies were conducted in bone marrow-derived macrophages (BMMs) with 
robust antiviral responses, it became clear that NS2 is an essential protein in the 
face of the innate immune response (15), with the OAS-RNase L pathway as its 
specific target (11). It is notable that the essential nature of NS2 is not ubiquitous 
among different sites of infection. NS2 is particularly important for viral replication 
and pathogenesis in the liver (13) where both Kupffer cells (liver resident 
macrophages) and liver sinusoidal endothelial cells mount robust OAS-RNase L 
responses, but not in hepatocytes, which do not (16). Similarly, NS2 is entirely 
unnecessary for MHV replication and pathogenesis in the brain (13), likely due to 
low basal levels of OAS expression (17, 18). These discoveries highlight the 
organ and cell type-specific nature of viral virulence factors, and demonstrate 
why some in vitro systems may not recapitulate natural infection or reveal 
important virus-host interactions. Additionally, important viral genes may become 
non-essential if viruses undergo a host-switch that results in tropism for a cell 
type that lacks robust RNase L activity. Such cross-species transmissions are 
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best understood in the context of zoonotic infections (19), but have surely played 
a significant role throughout the evolutionary history of RNA viruses (20, 21). 
Such a dynamic may underlie observations about the NS2 protein of porcine 
hemagglutinating encephalomyelitis virus (PHEV), which seems to have lost 
some of its catalytic activity as described in Chapter 2, and the total loss of NS2 
by HCoV-HKU1.  
 
 The work described in Chapter 2 strongly suggests that coronavirus PDEs 
are significant factors in promoting viral replication and fitness, given their near 
fixation in the Embecovirus genome. The identical position of the PDE in these 
genomes supports the idea that the gene was acquired a single time in the 
common ancestor of these viruses. The absence of a PDE NS2 gene in HCoV-
HKU1 further supports the importance of this gene, suggesting the gene may be 
disposed of if it becomes unnecessary. It is interesting, however, that HCoV-
OC43 and HCoV-HKU1, both respiratory viruses that infect the upper airway, 
differ in the presence of an NS2 gene. The difference may well be explained by 
differing cell tropisms that have not yet been identified. Studies using primary 
human airway epithelial cell cultures have found that HCoV-OC43 and HCoV-
HKU1 both exhibit a tropism for ciliated cells (22, 23), but it still is not known if 
they have identical tropisms during natural infection. We do know from studies of 
MHV that cell types differ dramatically in their ability to activate RNase L (13, 16). 
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 A critical outstanding question concerns what role the PDEs described in 
Chapter 2 play during natural infection. The chimeric MHV system we used to 
study these proteins is powerful but can only determine the capacity of PDEs to 
antagonize RNase L, not tell us how important the PDE is to promoting viral 
replication in their native context. The presence of a viral PDE alone is not 
sufficient to make inferences about the importance of the protein. PHEV, for 
example, encodes an NS2 PDE, but the PHEV NS2 is significantly less active in 
degrading 2-5A than the PDEs of MHV, HCoV-OC43 or Berne virus (BEV) 
despite no defects being obvious from its amino acid sequence (24). This 
suggests that NS2 is likely not required to promote viral fitness in PHEV target 
cells, while the presence of an RNase L antagonist in transmissible 
gastroenteritis virus (TGEV), indicates that porcine hosts do mount an RNase L 
response in the cells targeted by this virus (25).  Fully characterizing the role of 
the PDEs described in Chapter 2 will require the development of infectious 
clones, in vitro systems similarly powerful to the use of macrophages for studies 
of MHV, and perhaps where appropriate, animal models. An infectious clone 
does exist for HCoV-OC43, but the ATCC isolate it is based on is highly 
neurotropic following extensive serial passage in suckling mice and replicates 
poorly in human airway-derived cell lines (data not shown) (26, 27).  
 
 In contrast to our work with the viruses described in Chapter 2, we 
characterized the role of MERS-CoV NS4b in its native context. Thanks to the 
rapid development of a MERS-CoV infectious clone and a collaboration with Dr. 
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Ralph Baric (28), we were able to use recombinant MERS-NS4bH182R to study the 
interaction between this protein and the OAS-RNase L pathway (29). Notably, 
the PDEs encoded by MERS-CoV and similar viruses of the Betacoronavirus 
subgenus Merbecovirus appear evolutionarily distinct from the other viral PDEs 
studied by the Weiss laboratory, as they contain a longer N-terminus with a 
nuclear localization sequence (NLS), a shorter C-terminus, and are situated 
differently within the genome. An obvious possibility given these differences is 
that the Merbecovirus and Embecovirus PDEs were acquired independently from 
different hosts following the diversification of the Betacoronavirus genus. It is 
unknown whether these diverse viral PDEs share a host PDE ancestor and 
diverged following viral acquisition, or derive from different ancestors. Another 
possibility is that an ancestral virus in one subgenus acquired a host PDE that 
then diverged following horizontal gene transfer to an ancestral virus of the other 
subgenus. Unfortunately, the nucleotide and amino acid sequences of the viral 
PDEs are so highly divergent that constructing phylogenetic trees to identify host 
and viral ancestors is impossible. Obtaining additional high resolution structures 
of viral and host LigT-like 2H-PEs may offer a different approach to answering 
these questions. To date, only the structures of the cellular 2H-PEs AKAP18 (30) 
and USB1 (31) have been solved, and among viral 2H-PEs, only the rotavirus 
VP3 (32, 33) and MHV NS2 (34) structures are known. Structural information for 
other LigT-like 2H-PE family members, while perhaps not as informative as 
phylogenetic trees would be, could provide additional information on evolutionary 
relationships between cellular and viral proteins.  
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The fixation of ORF4b genes among MERS-CoV-like viruses suggest that, 
like the NS2 protein of MHV-like viruses, the NS4b protein is important for 
promoting viral fitness. As with the NS2 proteins, however, differences in NS4b 
proteins encoded by various MERS-CoV-like viruses suggest host or cell-type 
specific requirements for NS4b. Specifically, a MERS-CoV-like virus identified in 
European hedgehogs (35) encodes an N-terminal truncated NS4b that lacks an 
NLS. The ancestral merbecovirus presumably contained the NLS present in the 
NS4b of all other extant MERS-CoV-like viruses, and evidence suggests the 
subgenus originated in bats (36). It is probable that the selective pressure for 
nuclear localization of NS4b was relieved upon the establishment of this virus in 
a hedgehog host, while the cytoplasmic function of antagonizing RNase L 
remains necessary. As with PHEV, it seems more likely that the hedgehog 
coronavirus infects a cell type in which some PDE function is unnecessary, rather 
than there being a dramatic difference in innate immune repertoire.  
 
These subtle differences between Merbecovirus PDEs may offer 
opportunities for further teasing apart virus-host interactions and how such 
interactions can change when a virus enters a new ecological space. More 
immediately interesting to us, however, has been testing the hypothesis that 
MERS-CoV NS4b and its orthologs mediates additional functions beyond 
antagonism of OAS-RNase L, a hypothesis rooted in the clear differences 
between NS4b and MHV NS2. In testing this hypothesis, we have contributed to 
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an emerging paradigm shift about the function of viral phosphodiesterases, while 
major mechanistic questions remain unresolved. 
 
MERS-CoV NS4b – Phosphodiesterases beyond RNase L 
 Aside from my work growing our knowledge of Embecovirus NS2 proteins, 
I have worked to expand our understanding of the role of viral 2H-PEs more 
broadly in countering innate immune responses. Following the initial discovery 
that MERS-CoV NS4b was a putative PDE by Dr. Joshua Thornbrough, we 
quickly recognized differences compared to MHV NS2 that argued for a role 
beyond antagonizing RNase L. NS4b nuclear localization and description of its 
NLS had been previously reported (37, 38), but a nuclear viral PDE remained a 
novel concept. Our collaboration with Dr. Ralph Baric at the University of North 
Carolina, who engineered and recovered the recombinant MERS-CoV variants I 
have used (28, 29), MERS-NS4bH182R and MERS-NS4bNLSmut, has been critical to 
studying these presumed novel functions.   
 
 Although mechanistic questions remain to be answered, I have 
demonstrated that NS4b does indeed play a role during infection previously 
unknown for viral 2H-PEs. Mutation of either the NS4b catalytic site or its NLS 
results in increased activation of the interferon (IFN) antiviral response uncoupled 
from any activation or inhibition of RNase L, while making the equivalent 
mutation in MHV NS2 has no effect on IFN gene expression during infection of 
the same cell type (Fig 3.6). Another study has shown that NS4b inhibits NFκB 
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nuclear translocation (39), indicating that NS4b is truly a multifunctional 
antagonist of the innate immune response with an expansive repertoire of 
functions compared to the other viral PDEs the Weiss laboratory has studied and 
characterized.  
 
 As NS4b exhibits unique functions for a viral PDE, resolving the 
outstanding mechanistic questions will cement a paradigm shift regarding the 
function of these proteins. My work in this area provides some preliminary 
insights into at least some of its underlying mechanisms mediating antagonism of 
the IFN-driven antiviral response. Some studies have suggested that direct 
interactions with host proteins underlie NS4b innate immune antagonism. One 
study, for example, demonstrates that the NS4b NLS binds the same importin-α 
protein as NFκB, thus competitively inhibiting its nuclear import (39). It is possible 
that NS4b similarly prevents IRF3 nuclear import via cytoplasmic protein-protein 
interaction, which has some support in published work (38, 40). Other data, 
including ours (Fig 3.6) suggest NS4b inhibits IFN activation in the nucleus, 
downstream of IRF3 (37, 40) through a yet-unknown mechanism. Uniquely, our 
data suggests  that IFN antagonism by NS4b is mediated at least in part by its 
catalytic activity (Fig 3.6), though we cannot determine whether this occurs in the 
nucleus or cytoplasm. In fact, our observation of elevated IFN transcript levels 
induced by MERS-NS4bH182R and MERS-NS4bNLSmut, though of similar 
magnitude, may be a result of distinct mechanisms.  
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 Preliminary data suggests that NS4b, through its catalytic activity, reduces 
the abundance of intronic RNA during infection (Fig 4.4) which is likely though 
not certain to occur in the nucleus, as intronic lariats have been observed to 
accumulate in the cytoplasm of mammalian cells (41). The most obvious 
confounding factor in these data is that if NS4b mediates this effect in the 
nucleus, then mutation of the NLS should produce the same effect as mutation of 
the catalytic site, but does not. Two possibilities might explain this problem. The 
first is the possibility that despite mutation of the NLS the nuclear concentration 
of NS4b, while reduced, remains sufficiently high to reduce intronic RNA 
abundance. Two published studies suggest that mutation of the downstream 
basic motif (KRR) of the NS4b NLS is less potent at abrogating nuclear 
localization than mutation of the first motif (RKR) (37, 39). I have not done 
quantitative analysis of NS4b localization, but these reports are consistent with 
my general observations. Nevertheless, this remains a worthwhile line of inquiry 
as mechanistic studies of NS4b proceed. The second possibility may be that 
while NS4b normally acts to reduce the abundance of intronic RNA in the 
nucleus, that when NS4b is excluded from the nucleus, such RNA escapes to the 
cytoplasm, where it might still be targeted by NS4b. Mutating the first basic motif 
of the NS4b NLS is impossible in recombinant MERS-CoV without inducing non-
synonymous mutation in NS4a or splitting ORF4a and ORF4b as was done in a 
recent study (39), but which we chose not to do with the understanding that 
NS4b expressed by MERS-NS4bNLSmut might not be entirely excluded from the 
nucleus. One possible approach for resolving this issue would be to develop a 
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system in which different NS4b constructs are expressed outside the context of 
infection but which would recapitulate the observation of increased intronic signal 
upon mutation of the NS4b catalytic site. In such a system, various NS4b 
constructs could be expressed such as mutation of the first basic motif or 
mutations that enhance the strength of the NLS alone or in combination with the 
catalytic mutation. I attempted to generate A549 cell lines stably or inducibly 
expressing some of these proteins, but was not able to detect expression of 
NS4b. It is possible that another cell line would be more amenable to generating 
such a system.  
 
 The most significant outstanding question is what accounts for the 
increased intronic RNA when MERS-CoV NS4b is catalytically inactive. I have 
made this observation from introns of two interferon stimulated genes (ISGs), 
IFIT2 and DDX58, which encodes the dsRNA sensor RIG-I. IFIT2 has a single 
intron and I have confirmed this phenomenon with multiple primer sets, while 
DDX58 is a large gene with over a dozen introns, the first of which is represented 
in my data. Our preliminary hypothesis is that the increased signal reflects a 
greater abundance of intronic lariats, suggesting wild-type NS4b enhances lariat 
turnover (Fig 5.1). We find this possibility particularly intriguing because of the 
2’,5’ phosphodiester bond that forms the lariat structure (41-43). 2’,5’ 
phosphodiester bonds are relatively rare, with the two most obvious occurrences 
being in 2-5A and intronic lariats.  
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 Determining whether there is in fact an accumulation of lariats during 
MERS-NS4bH182R infection is a necessary and immediate priority. Initially, these 
experiments should focus on IFIT2 and DDX58. The first GAPDH intron does not 
exhibit increased 
abundance due to NS4b 
catalytic mutation, but 
otherwise trying to predict 
which introns might be 
affected and should 
therefore be studied in a 
targeted fashion is 
exceedingly cumbersome. 
I have attempted to 
determine whether 
circular IFIT2 intron 
accumulates during 
MERS-NS4bH182R 
infection by northern blot, as circular RNAs, like circular DNA, will appear on a 
gel to be larger than its actual size (41). However, I was not able to detect even 
the mature IFIT2 mRNA, likely to be more abundant than any intronic IFIT2 
mRNA, presumably because during MERS-CoV infection it remains a low 
abundance transcript. As an alternative and likely more sensitive approach, I 
propose RNase R digestion (41) of linear RNA from A549DPP4 cells infected with 
Figure 5.1 Hypothesized model for NS4b acceleration of lariat 
debranching. A) We hypothesize that WT NS4b accelerates 
debranching to prevent the accumulation of lariats during 
infection, which may induce increased transcriptional activity B) In 
this scenario NS4bH182R fails to accelerate debranching, leading to 
an accumulation of lariats due to escape from or saturation of the 
constitutive debranching machinery. The aberrant accumulation of 
nucleic acids may promote antiviral signaling, particularly if they 
escape to the cytoplasm. 
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WT MERS-CoV, MERS-NS4bH182R, and MERS-NS4bNLSmut, followed by the same 
RT-qPCR analysis as described in Figure 4.4. If the enhanced intronic RNA 
signal is due to increased abundance of IFIT2-derived circular intronic RNA, this 
signal should persist even after RNase R digestion. Should we obtain this finding, 
high-throughput RNA sequencing would enable a more complete understanding 
of how inactivation of the NS4b catalytic site affects intron turnover, including 
determining whether the accumulation of intronic RNA represents persistent 
lariats or re-circularized, debranched introns (41, 44).  
 
Biochemical approaches must also be utilized in testing this hypothesis 
and would benefit from extensive collaboration as they fall outside the Weiss 
laboratory area of expertise. We have previously demonstrated that NS4b has 
2’,5’ phosphodiesterase activity, but it is unclear whether it is able to debranch 
introns, a critical piece of information towards supporting or refuting our 
hypothesis. Therefore, NS4b could be included in an in vitro debranching assay 
with the cellular debranching enzyme DBR1 as a positive control (45). 
Additionally, solving the NS4b structure in complex with known (2-5A) or possible 
(lariat) substrates would prove informative as to whether NS4b has the capacity 
to debranch introns (46) as DBR1, a phosphoesterase of a distinct family, does. 
Although no 2H-PE has yet been shown to bind and debranch introns, to our 
knowledge no one has looked, the cellular 2H-PE USB1 sets a clear precedent 
for such proteins to associate with components of the spliceosome.  
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 The possible biological significance of intron accumulation is difficult to 
predict. Although the field studying stable intronic RNAs is expanding, there is 
still little agreement on their function, or if there is one. In the context of virus 
infection, we can presume that if MERS-CoV has acquired a means of preventing 
lariat accumulation, then such accumulation is likely to prove detrimental to the 
virus in some way. The accumulation of unusual types of nucleic acid in 
unexpected cellular compartments is a classic trigger of antiviral responses. 
Examples include activation of cGAS by cytoplasmic DNA of mitochondrial or 
viral origin (47-50), and of RIG-I and MDA-5 by cytoplasmic dsRNA (51, 52). With 
some evidence now available that introns which escape debranching by the 
endogenous cellular machinery can accumulate in the cytoplasm (41), it is 
possible to consider that such accumulation might trigger or enhance antiviral 
responses (Fig 5.1). However, the literature surrounding this remains limited and 
our data is preliminary. Much work remains to be done before any conclusions 
should be considered.  
 
 A second possibility, in contrast to the hypothesis that NS4b mutation 
slows intron turnover, is that the elevated intron signal is due to intron retention. 
Intron retention is a well-recognized mechanism of gene expression and 
translational regulation (53-55). Typically, intron retention between exons will 
result in nonsense mediated decay (NMD) of the mRNA, which can regulate 
protein levels post-transcriptionally (55). In contrast, intron retention in other 
regions of an mRNA, such as in untranslated regions, can actually enhance 
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translation (56). Since the increased intron signal from IFIT2 and DDX58 comes 
from an intron between exons, if it is due to a failure to excise the intron during 
splicing the mRNA is likely directed towards degradation by NMD.  I have 
attempted to quantitatively assay for intron retention by RT-qPCR, but low 
abundance of transcripts containing an intact exon-intron junction has precluded 
success so far. It may be possible to induce sufficiently high levels of IFIT2 or 
DDX58 pre-mRNA by stimulation with high levels of IFN, but prospects for 
quantifying such transcripts during MERS-CoV infection remain remote. The best 
opportunity to determine whether mutation of NS4b results in more frequent 
intron retention will be during analysis of the RNA sequencing experiment 
described above using established computational pipelines for quantifying intron 
retention (44). If my data does reflect intron retention, it would seem likely this 
results in a higher percentage of less functional ISG mRNA, and therefore a 
dampened innate immune response. Given that NS4b is an innate immune 
antagonists, I would expect that mutation of NS4b would result in a more 
effective antiviral response. This is one reason I consider it more likely that NS4b 
participates in intron turnover, rather than promoting correct splicing of cellular 
mRNAs, including those transcribed from antiviral genes. 
 
 Conducting the experiments described above will not be exhaustive, as 
even if our hypothesis is correct new questions and challenges will surely arise. 
However, this should constitute a roadmap for pushing forward with the 
exploration of novel viral phosphodiesterase interactions with the host. One 
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critically important question is not addressed because we lack preliminary data 
supporting any particular hypothesis. Specifically, we still do not know how NS4b 
inhibits the expression of IFNL1. That it does so is widely reported in the 
literature (37, 38, 40, 57) but we uniquely found that it does so via its catalytic 
activity. It is possible that, at least in the case of MERS-NS4bH182R, the increased 
IFNL1 transcript abundance is actually downstream of intron accumulation, but 
support for such a mechanism requires more experimental evidence of intron 
accumulation during MERS-NS4bH182R infection and of such accumulation 
triggering antiviral signaling. It has previously been reported that nuclear NS4b 
blocks IFN gene expression downstream of IRF3 activation (40). The mechanism 
for doing so is unknown. Although I did not detect IRF3 activation during MERS-
CoV infection there is likely a low level of activation underlying the modest IFN 
expression that does occur. There also remains the issue that the full picture of 
NS4b interactions with the host antiviral response continues to increase in 
complexity. It has now been identified during infection as an RNase L antagonist 
(29), an inhibitor of NFκB nuclear translocation (39), and an IFN antagonist 
(Chapter 3) (57). Additional layers of complexity may be surprising, but are 
supported by preliminary data and can only be demonstrated or dispensed with 
through further experimentation. These experiments have the potential to 
mechanistically characterize an entirely novel function for viral 
phosphodiesterases, expanding our understanding of how viruses interact with 
their hosts using host genes repurposed to their own ends. 
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Conclusion 
The work described in this thesis covers a broad array of virus-host 
interactions mediated by viral phosphodiesterases. The understanding of these 
proteins as modulators of innate immunity has accelerated over the last decade 
after the prototype, MHV NS2, was initially considered dispensable (14). NS2 
was computationally characterized in 2002 (12), but its full importance has only 
been recognized in a series of much later studies (11, 13, 16). A parallel body of 
work has begun to illuminate the function of cellular 2H-PEs in intracellular 
signaling (30, 58) and RNA processing (31, 59-61). I have been able to expand 
the range of viral PDEs known to interact with OAS-RNase L (24) and initiated 
what may develop into a paradigm shift in the range of known functions mediated 
by these proteins. We have shown for the first time that viral phosphodiesterase 
activity modulates an element of the innate immune response apart from the 
OAS-RNase L pathway. Yet, much opportunity remains for elucidating potential 
interactions and mechanisms underlying this phenomenon. These opportunities 
and the potential experiments described herein can serve as the basis of 
continued research into this previously unrecognized role of 2H-PEs. In addition, 
fundamental questions about intron fate and its biological consequences may be 
addressed as well. Therefore, the work described in this thesis has both 
advanced our scientific knowledge of coronavirus-host interactions and 
generated even more new questions in this area, creating exciting prospects for 
future research.  
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